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From the Editor’s Desk
The Department of Pathology & Laboratory
Medicine is committed to providing high quality
diagnostic services for physicians and hospitals
nationwide.
One of the functions of the Department is to
update physicians throughout Pakistan about the
advancement in laboratory sciences and the services
available at the Clinical Laboratory for disease
diagnosis, through our Laboratory Updates and this
newsletter, LABRAD.
The current issue of the LABRAD focuses on
measurements related to bone disorders in an
attempt to give readers a better understanding of
the diagnostic modalities available at Aga Khan
University Hospital Clinical Laboratories.
Bone disease is a vast topic which interests a
diverse group of medical professionals such
as: internists, rheumatologist, orthopaedics,
endocrinologist, gynaecologists, paediatricians
and geriatrics, researchers in anatomy, physiology,
nutrition, biochemistry, pathology and imaging.
Diversity of interest is due to a combination
of problems ranging from malnutrition in the
developing world to the aging populations of the
developed world.
Several factors may influence the choice of a
method for the measurement of bone disease. A
major limiting factor in establishment of a service

for measurement of bone diseases is the local
availability of equipment and methodology, and
also the availability of the required expertise and
knowledge for the interpretation of results. Choice
of the tests also depends on the type of information
required from investigating a patient suspected of
having a bone disease and achieving this aim as
economically as possible in less time and money.
This issue concentrates on common bone
related clinical problems; focusing on practical
usefulness of various tests available for diagnosis
and management of bone diseases in the field.
Biochemical bone profiles have been developed
in the section of chemical pathology to help the
physician in evaluating a patient suspected of
having metabolic bone diseases. Combination of
information on different microbiological tools for
facilitating management of bone infection along
with diagnostic tools available for identifying
disorder like ankylosing spondylitis are also
presented. On the whole this is a broad sweep of
information collected through individual disciplines
and we hope it will improve as our newsletter
evolves through a cyclic process of learning and
sharing with our readers.
We hope this edition would help increase your
knowledge banks and would answer many of your
questions. We are hopeful for making this issue a
useful document for future reference in the bone
disease area. Happy reading!
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Biochemical Bone Profiles Available at Clinical
Laboratory of Aga Khan University Hospital
Dr Farhan Javed Dar
Chemical Pathology

The utility of bone profiles in screening and
diagnosis of bone diseases have a profound effect
upon bone health. Choosing any screening profile
helps to rule out metabolic bone diseases such as
vitamin D deficiency, osteoporosis. Panels are made
to make clinical interpretation easy for physicians
and economical for patients.
Following profiles are available at Clinical
Laboratory AKU for diagnosis and monitoring of
bone disorders. Only 5 ml of blood is sufficient for
any one of the panel as shown in the Table.

Commonly encountered bone diseases include those
related to vitamin D deficiency (rickets in children
and osteomalacia in adults), osteoporosis,
osteogenesis, imperfecta and Paget’s disease of bone.
Bone disease can lead to fragile and brittle bones,
which break easily.
AKUH clinical laboratory is now providing
Bone Health Panel, (please refer to the table
below) which helps in assessment of bone health.
This profile is intended to screen, investigate
and monitor patients with disorder of calcium

Biochemical Bone Profile
Bone Health Panel

Osteoporosis Panel

Calcium

Calcium

Phosphorus

Phosphorus

Albumin

Albumin

Magnesium

Alkaline phosphatase (ALP)

Alkaline phosphatase (ALP)

25-hydroxy vitamin D (25-OHD)

Creatinine

Intact parathyroid hormone (iPTH)

Intact parathyroid hormone (iPTH)

N-telopeptide of type I collagen (NTx)

25-hydroxy vitamin D (25-OHD)

Bone Health Panel
Bone health is important throughout the lifetime of
an individual. Bones protect our internal organs from
damage, they are the factory of our blood cells and
are the storehouse for minerals and nutrients (such
as calcium and phosphorus) needed in the body.
With all of these critical functions for our health,
understanding how to maintain and build healthy
bones is an important part of investigating for a
healthy future.
It is especially important to build strong and healthy
bones during childhood and teen years to avoid
osteoporosis and other bone problems later in life.
After the mid-30s, bone loss slowly begins to occur.
Women lose bone quickly after menopause.
Importantly, healthy habits can help to limit the bone
loss that occurs. Taking care of our bones when we
are young will help prevent problems in the future.
4

and bone metabolism. It provides answer to
the potential clinical questions that a physician
seeks when investigating for metabolic bone
diseases for example; does my patient have
hypocalcaemia or hypercalcaemia? If there is
hypercalcaemia, is it due to hyperparathyroidism
or a parathyroid hormone independent cause? If it
is hypocalcaemia, is it due to parathyroid failure,
vitamin D deficiency or renal failure? Does my
patient have hypomagnessemia? If the patient has
aches and pains or unexpected fracture then is it
due to metabolic bone disease?
Osteoporosis Panel
Osteoporosis is a systemic skeletal disorder
characterised by low bone mass and micro
architecture deterioration of bone tissue with
a consequent increase in bone fragility and
susceptibility to fracture.
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According to WHO by 2025, almost 3 million of
the global population will suffer from osteoporosis
which will be expected to rise to 6.3 million by
2050. About 75 percent of this 6.3 million hip
fractures will occur in the developing countries,
mainly due to projected large increase of aged
population. Osteoporosis is a costly disease due
to its chronic nature, severity of its complications
and means required to treat it. Osteoporosis is

diagnosed late as patient remains asymptomatic
until fracture occurs. AKUH Clinical Laboratory
is providing Osteoporosis Panel, mentioned in
the above table, which helps in assessment of
osteoporosis.
It is to be noted that diagnosis should be made in
correlation with clinical picture and Dual-energy
X-ray absorptionetry (DXA) results.

Ionized Calcium Determination in Clinical
Labortory
Dr Lena Jafri
Chemical Pathology

Plasma calcium exists in three forms ionized (iCa)
(45 to 50 per cent), protein bound (40 per cent) and
calcium complexed with anions (10-15 per cent).
Although all the forms are in equilibrium with each
other, only the plasma iCa has been reported to
be active at cellular level. This parameter has also
been called ‘free’ or ‘ionic’ calcium. It is considered
the best indicator of calcium status because it
is biologically active and tightly regulated by
parathyroid hormone (PTH) and 1, 25 dihydroxy
vitamin D. Total calcium level does not give an
indication of what is available at the cellular level.
Only disturbances in iCa are physiologically
relevant.

Analysis of iCa is technically demanding. The sound
analytical performance of today’s iCa analyzers
using ion selective electrode (ISE) technology
have made measurements accurate and precise.
iCa recently introduced in Aga Khan University
Clinical Laboratory after thorough research and
understanding of Clinical Laboratory Standard
Institute Guidelines (CLSI) for sample handling,
storage and transportation. Table 1 shows the
precautions to be taken prior to blood sampling for
iCa determination and collection.
The clinical usefulness of measuring iCa rather
than total calcium is more in disorders with plasma

Table 1. Recommendations for Specimen Collection of iCa as per CLSI Guidelines
Precollection Variables and
Recommendations
Have the patient rest for 5-10 min before
collecting blood

Collection Techniques
If a series of tubes must be collected, fill gel tube for iCa first

Ensure that the patient has not eaten for at least 4 hours

Do not leave the tourniquet on for more than 3 minutes

Collect specimens under consistent conditions
ideally the patient should be seated

Do not allow the patient to exercise the forearm or make a fist

Fill gel tubes completely
Handle specimen anaerobically (do not open the tube until
analysis)
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protein abnormalities like liver failure, protein losing
nephropathy, burns, cardiac failure or malnutrition.
iCa determination is more useful in those undergoing
major surgery who have received citrated blood/
platelets, heparin, or intravenous calcium.
It should be the test of choice when neonatal
hypocalcemia is suspected, especially if bicarbonate
is given to neonates with hypocalcemia.
Rapid measurement of iCa in intensive care
units is helpful in cases with sepsis and acid base
disturbances. It has been documented that the use of
total calcium is unreliable in cases where there is a
change in the protein-calcium binding characteristics

as in patients with hypergammaglobulinemia or a
decrease/increase in pH. An increase in blood pH is
associated with a decrease in iCa a decreased blood
pH is associated with an increased iCa.
Ionized calcium is also useful in cardiopulmonary
bypass and during hemodialysis where maintenance
of good cardiac function is essential. During dialysis
monitoring a slight positive calcium balance is
important for maintaining good cardiac contractility.
Ionized calcium is the best means to monitor this.
Literature shows that iCa rather than total
calcium is more useful in malignancies, hypo/
hyperparathyroidism and pancreatitis.

Parathyroid Hormone Disorders and Issues
of Testing
Dr Syed Talha Naeem
Chemical Pathology

Parathyroid hormone (PTH) is secreted by the
parathyroid glands and regulates serum calcium (Ca)
through its effects on the bone, kidney and intestine.
PTH secretion is stimulated by decrease in serum Ca
and magnesium and an increase in serum phosphate,
which in turn raises serum ionized Ca levels through
direct action on bone and the kidneys. Long-term
regulation of total body Ca by PTH occurs through
its stimulation of vitamin D metabolism.
PTH can be measured in the blood in several
different forms: intact PTH; N-terminal PTH;
mid-molecule PTH, and C-terminal PTH. An intact
PTH (iPTH) provides a better index of parathyroid
function and is the test available in AKUH clinical
laboratory for clinical use.
PTH is secreted in episodic or pulsatile fashion
with an overall circadian rhythm characterised by
a nocturnal rise. Measurement of iPTH on more
than one occasion should minimise the effect of
episodic secretion and circadian rhythm. Because
of the nocturnal rise in iPTH levels, samples should
be collected in the morning, preferably after an
overnight fast.
Determination of iPTH is useful in the differential
diagnosis of disorders of bone and mineral
6

metabolism, including hypocalcaemia and
hypercalcaemia, renal failure and secondary
hyperparathyroidism; when PTH increases long
before Ca becomes abnormally low.
PTH is elevated in the majority of patients with
primary hyperparathyroidism. It is below normal
or in the lower half of the reference interval in
most patients with nonparathyroid hypercalcemia
including hypercalcemia-associated malignancy.
In cases with hypercalcemia, PTH estimation
should be performed before initiating any therapy
to reduce serum Ca; as PTH secretion may be
stimulated by declining but still elevated levels
of serum Ca. This can complicate the differential
diagnosis of hypercalcaemia. In the majority of
patients with hypercalcaemia associated with
malignancy, iPTH is suppressed to levels below
normal or at the lower end of the normal reference
interval. Elevated levels of iPTH in patients with
hypercalcemia and malignancy suggest coexisting
hyperparathyroidism and malignancy, because
ectopic PTH production appears to be extremely
rare.
In secondary hyperparathyroidism, iPTH is
increased before total or free calcium becomes
abnormally low, a consequence of homeostatic
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mechanisms for maintenance of serum Ca.
Consequently, PTH is more sensitive than Ca
for identifying secondary hyperparathyroidism.
Subnormal or normal PTH is observed in the
majority of patients with hypoparathyroidism;
such concentrations are inappropriately low for
patients with hypocalcemia.
In patients with end-stage renal disease,
measurement of iPTH is helpful in assessing
parathyroid function, in estimating bone turnover,
and in improving management. Patients with
high turnover bone disease because of secondary
hyperparathyroidism (advanced osteitis fibrosa) have
the highest concentrations of PTH, whereas patients
with low-turnover, adynamic bone disease, including
osteomalacia, have the lowest concentrations.
Intermediate levels are found in patients with lowturnover adynamic (aplastic) disease and early
osteitis fibrosa. Considerable overlap in iPTH
levels is apparent between the various forms of renal
osteodystrophy.
iPTH is also useful intraoperatively, for assessing
the completeness of parathyroidectomy and
facilitating minimally invasive parathyroid surgery,
thereby improving cost-effectiveness and cosmetic
outcomes.

PTH levels may be altered in some patients with
hyperthyroidism and hypothyroidism and may
increase after treatment with lithium carbonate.
PTH concentrations are inversely correlated with T3
levels in hyperthyroid patients, increase in patients
who become hypothyroid after radioactive iodine
treatment, and decrease with replacement therapy;
changes apparently mediated by serum Ca. Chronic
lithium carbonate therapy has been reported to
increase parathyroid gland size and circulating intact
PTH. Drugs that may increase PTH levels include
phosphates, anticonvulsants, steroids, isoniazid,
lithium, and rifampicin.
Because of the physiological relationship between
circulating Ca and PTH, it is always important to
interpret PTH results in the light of total or ionized
Ca levels. Indices of renal function, measurements
of albumin, as an adjunct to measurement of total
calcium levels and determinations of phosphorus,
chloride, and magnesium levels may also aid in
the interpretation of PTH and Ca results. It should
also be remembered that hypercalcemia and
hypocalcemia may be secondary to disordered
vitamin D metabolism. For diagnostic purposes PTH
results should always be used in combination with
the clinical examination, patient medical history, and
other findings.

Tubular Maximum Reabsorption Rate of
Phosphate to Glomerular Filtration Rate
(TmP/GFR)
Dr Noreen Sherazi
Chemical Pathology

Phosphate filters entirely through the glomeruli
but is then largely reabsorbed in the proximal part of
the proximal renal tubule. Several factors influence
the tubular reabsorption of phosphate (Table 1) by
acting on the sodium/phosphate co transporters.
Tubular reabsorption of phosphate depends on
plasma phosphate and glomerular filtration rate and
is not a satisfactory indicator of tubular phosphate
handling. This has led to increasing use of ‘tubular
maximum for phosphate corrected for GFR (TmP/
GFR)’, a factor independent of plasma phosphate
and renal functions for assessment of renal phosphate
handling. TmP/GFR (Normal 2.8-4.4 mg/dL) is an

index of renal threshold for phosphate which can
be determined directly by the formula TmP/GFR
= Plasma phosphate - (urine phosphate x serum
creatinine)/urine creatinine.
Assessing renal reabsorption of phosphorus is needed
in a variety of pathological conditions associated
with hypophosphatemia including hypophosphatemic
rickets, tumour-induced osteomalacia and tumoral
calcinosis. It is also used in adjusting phosphate
replacement therapy in severe deficiency states;
like conditions that cause phosphate redistribution
(e.g. glucose infusion, respiratory alkalosis), so if
7
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Table 1. Factors Affecting Tubular Reabsorption of Phosphate
Factors that decrease renal phosphate absorption

Factors that increase renal phosphate absorption

Phosphate-free diet

High dietary phosphate intake

Respiratory acidosis, metabolic alkalosis

Respiratory alkalosis, metabolic acidosis

PTH, PTHrP, EGF, glucocorticoids, catecholamines, calcitonin,
1,25(OH)2 D3

GH, IGF1, thyroid hormones (T3), insulin

Diuretics
Phosphatonins

hypophosphataemia persists, a low (fasting) TmP/
GFR indicates the need for phosphate replacement.
In the treatment of severe phosphate deficiency,
TmP/GFR can be used as an indicator of intracellular
repletion.
The measurement of TmP/GFR along with other
parameters is required for diagnosis of X-linked
hypophosphataemic rickets and hereditary
hypophosphataemic rickets with hypercalciuria.

Measurement of TmP/GFR is central to the diagnosis
of oncogenic osteomalacia in addition to other
parameters
We, at AKUH clinical laboratory, are starting
this test which will required at least 6-8 hours
fasting serum sample for phosphate and creatinine
and simultaneously taken spot urine sample for
phosphate and creatinine. TmP/GFR will then be
calculated from above mentioned parameters.

LABRAD Quiz
Dr Hafsa Majid
Chemical Pathology

Question #1

1.3: How would this be treated?

A three-week-old girl was brought to the emergency
room because of intermittent twitching of her left
limbs for 4 days. The girl had been born normally
at 39 weeks of gestation and was being breast-fed.
Examination was unremarkable. Her biochemical
investigations were:

Question #2

Na+ : 125mmol/l (135-145 mmol/l)		
Cl- : 100mmol/l (101-111 mmol/l)		
K+ : 2.8mmol/l (3.6-5.0 mmol/l)
HCO3 : 30mmol/l (23-28 mmol/l)
Ca+ : 4.5mg/dl (8.4-10.2mg/dl)		
Albumin : 2g/dl (3.2-5.5g/dl)
PO4 : 10mg/dl (2.5-4.6 mg/dl)
PTH : <4pg/l (16-87pg/ml)

A 60-year-old female came to ER due to
fracture neck of femur after a minor fall. Her
past complaints were of generalised body
aches and bone pains with difficulty in rising
from sitting position since two year. She was
a known case of hypertension for the past 20
years and taking antihypertensive since then.
She was diagnosed to be osteoporotic and was
considered for bisphosphonate therapy.
2.1: What is the most likely cause of body aches
in the patient?

1.1: What is the diagnosis?

2.2: What biochemical test can be performed to
confirm diagnosis?

1.2: Which other bone mineral is required for 		
optimal parathyroid function?

2.3: How will you monitor the response to 		
bisphosphonate therapy?
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Renal Osteodystrophy: A Disturbed Metabolic
Aspect of Renal Failure
Dr Sahar Iqbal
Chemical Pathology

Renal osteodystrophy is a common complication
of chronic kidney disease (CKD). It is part of a
broad spectrum of disorders of mineral and bone
metabolism that develop in this clinical setting
and result in both skeletal and extra skeletal
consequences. The term CKD-Mineral and
Bone Disorder (CKD-MBD) has been recommended
to be used to describe a broader clinical syndrome
that develops as a systemic disorder of mineral
and bone metabolism in CKD. The manifestations
include abnormalities of calcium, phosphorous,
parathyroid hormone (PTH) or vitamin D
metabolism; abnormalities in bone turnover,
mineralisation, volume, linear growth or strength;
and vascular or other soft tissue calcification.
The term renal osteodystrophy should be used
exclusively to define alterations in the bone
morphology associated with CKD. This is a single
measure of the skeletal component of the systemic
disorder of CKD-MBD that is quantifiable by
histomorphometry of bone biopsy. The abnormalities
of the bone in the setting of CKD may manifest
as high turnover bone disease (ostietis fibrosa
or secondary hyperparathyroidism), dynamic
bone disease, osteomalacia and mixed renal
osteodystrophy.
Biochemical markers for diagnosing renal
osteodystrophy are intact PTH (iPTH), vitamin D
(25OHD), blood calcium and phosphorus levels and
bone turn over markers such as alkaline phosphatase
and N-telopeptide of type I Collagen (NTx).
The pathogenesis of osteodystrophy is complex.
The cycle starts with the renal failure and
retention of phosphate, inhibiting calcitriol (1,25
dihydroxy vitamin D) synthesis and decrease
in calcium through a reduction in intestinal
calcium absorption. Hypocalcaemia stimulates
PTH secretion causing high turnover renal
osteodystrophy.
The biochemical picture of high turnover renal
osteodystrophy usually is an increase in blood

PTH, bone alkaline phosphatase and phosphate
concentration and low calcium and 25OHD levels.
Low turnover bone disease is commonly observed
in dialysis patients, but has been described in
some cases even before dialysis. Adynamic bone
disease is associated with the over suppression
of parathyroid gland activity due to high calcium
intake (from diet, dialysate or calcium-containing
phosphorus binders) and/or administration of
vitamin D analogs in excess.
Patients with adynamic bone disease have lower
blood concentrations of iPTH that may fall
below the recommended target range of 150-300
pg/ml of iPTH, resulting in a bone turnover rate
that is below normal. In these circumstances, the
bone may not take up calcium for incorporation
into new bone and any excess calcium may
predispose to calcification in soft tissues.
Currently in the United States, approximately
25 per cent of patients undergoing dialysis have
a iPTH concentration above the target range
(high-turnover disease), approximately 25 per
cent have a PTH concentration within the target
range and 50 per cent have a PTH concentration
below the target range (adynamic bone disease).
The ultimate goal of drug therapy in
the management of CKD is to prevent
complications of CKD, specifically bone
disease and extra skeletal calcification. Need
for the evaluation, treatment and monitoring
of bone metabolism is to prevent secondary
hyperparathyroidism. At stage 3 CKD, serum
calcium, phosphorus and iPTH concentrations
should be evaluated. After initial assessment,
routine monitoring should be performed (see
Table 1). Appropriate management requires a
balanced diet, phosphorus binders and active
vitamin D analogs. The recommended ranges
for corrected calcium, phosphorus and iPTH for
different stages of CKD for kidney
diseases outcomes quality initiative are shown
in Table 2.
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Table 1. Monitoring of frequency of calcium, phosphorus and intact PTH in different stages of CKD kidney diseases
National kidney foundation. Clinical practice guidelines for bone metabolism and disease. Am J Kidney Dis 2003; 42(4 supp 3): S12
Stage of CKD
Measurement of iPTH
			
2

Every 12 months

Every 12 months

2

Every 3 months

Every 3 months

Every 3 months

Every month

3 (30-59 ml/min/1.73 m

4 (15-29 ml/min/1.73 m
2

5 (<15ml/min/1.73 m

Measurement of Calcium and
Phosphorus

Table 2. Recommended ranges for phosphorus, corrected calcium and PTH for different stages of CKD.
National kidney foundation. Clinical practice guidelines for bone metabolism and disease. Am J Kidney Dis 2003; 42(4 supp 3): S12
Stage of CKD

Phosphorus
(mg/dl)

Corrected calcium
(mg/dl)

Serum PTH
(pg/ml)

2

2.7-4.6

Normal range

35-70

2

2.7-4.6

Normal range

70-110

3.5-5.5

8.9-9.5

150-300

3 (30-59 ml/min/1.73 m

4 (15-29 ml/min/1.73 m
2

5 (<15ml/min/1.73 m

Osteopenia and Osteoporosis in Beta
Thalassemia Major
Dr Huma Mansoori and Dr Shabina Sikandar
Haematology

Beta thalassemia major (TM) is an inherited autosomal
recessive disorder in which synthesis of beta globin
chains is compromised due to mutation of beta globin
gene culminating in ineffective erythropoiesis.

decreased bone strength with an increased risk of
fracture.

The anaemia manifests at 6 to 9 months after
birth as haemoglobin switches from HbF to HbA
with features like failure to thrive, poor feeding,
recurrent infections, pallor and enlarged spleen. In
untransfused patients haemoglobin level ranges from
3 to 6 gm/dl. However, regular blood transfusion and
compliance with prompt iron chelation therapy has
markedly improved life expectancy of thalassemics,
but morbidity due to its chronic complications like
osteopenia and osteoporosis remains there.

The frequency of osteopenia or osteoporosis in
well-treated patients of TM is approximately 4050 per cent which clearly depicts that despite the
normalisation of haemoglobin levels, adequate
hormone replacement and effective iron chelation;
thalassemics continue to show an unbalanced bone
turnover and an increased resorption resulting
in seriously diminished BMD. Bone disease in
thalassemia is manifested by diffuse bone pain,
spinal deformities like scoliosis, nerve compression
and various degrees of osteopenia, osteoporosis and
spontaneous fractures.

Osteopenia refers to bone mineral density (BMD)
that is lower than normal peak BMD but not low
enough to be classified as osteoporosis while
osteoporosis is characterised by low bone mass
and disruption of bone architecture, resulting in

Factors contributing to osteoporosis and osteopenia
in thalassemics include iron overload resulting in
endocrinopathies; which directly or indirectly leads
to decreased bone mass. There is marrow expansion
due to increased erythropoiesis causing mechanical

10
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interruption of bone formation leading to cortical
thinning of bones. In addition, osteoblasts are also
affected by direct iron toxicity as well as due to liver
disease. Chelation therapy with desferrioxamine
inhibits DNA synthesis, osteoblast and fibroblast
proliferation, osteoblast precursor’s differentiation
and collagen formation, whereas in high doses it
enhances osteoblast apoptosis.
The serum biochemistry is usually unhelpful in
diagnosis of osteoporosis because the levels of
calcium, phosphate and PTH are generally normal.
However, markers of bone turnover such as serum
alkaline phosphatase, serum osteocalcin, and N
telopeptide of Type I Collagen (NTx) may be raised
in osteoporosis in TM. Dual energy x-ray absorption
(DXA scan) is also commonly used to assess bone
mineral density but it should be kept in mind that it
may fail to provide accurate and precise information
on osteoporosis in thalassemics as they have spinal
degenerative skeletal changes, which can be detected
only by MRI and is likely to interfere with BMD
values, resulting in false diagnosis of bone disease.
Vitamin D deficiency can also co-exist.
Following therapeutic strategies should be
undertaken to prevent and treat osteopenia/
osteoporosis in TM.

l

lifestyle measures should be encouraged such as
physical activity and smoking quitting.

l

calcium and vitamin D intake during skeletal
development increases bone mass in adult life
with the final goal to prevent bone loss and
fractures.

l

induction of puberty at a proper age and
treatment of hypogonadism with hormone
replacement therapy shows quite promising
results to prevent osteoporosis and other bone
deformities.

l

calcitonin, a potent inhibitor of osteoclasts, in
combination with calcium and vitamin D has
shown to decrease bone pain and radiological
signs of osteoporosis.

l

alendronate, pamidronate, and zoledronic
acid have shown efficacy in osteoporotic patients
with TM either with normal or impaired gonadal
function but further research in the therapeutic
trials with bisphosphonates is needed to allow
definite conclusions especially in our setting
where vitamin D deficiency is widely prevalent.
However, they may be used as a second line
treatment if the above strategies have failed.

Role of β2 Microglobulin in Multiple Myeloma
Dr Mehreen Imran
Haematology

Multiple myeloma is a B cell malignancy
characterised by monoclonal accumulation of
abnormal plasma cells in the bone marrow (Fig.
1). The clinical signs and symptoms of myeloma

are heterogeneous and include bone complications,
symptoms of impaired formation of blood cells
and hyperviscosity, renal dysfunction, infections,
peripheral neuropathy and extra medullary disease.
Multiple myeloma constitutes about 15 per cent of
the haematological malignancy. The disease develops
in one to four per 100,000 people per year. It is
more common in men, and is twice as common in
blacks as it is in whites. With conventional treatment,
the prognosis is three to four years, which may
be extended to five to seven years or longer with
advanced treatments.

Fig. 1. Bone marrow aspirate demonstrating plasma cells of multiple myeloma

Diagnostic work up for myeloma is shown in
Table 1. One of the laboratory parameter is β2
microglobulin
11
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Table 1. Laboratory and Radiological Work ups for Multiple
Myeloma Available at AKUH
Laboratory Tests
Full blood count, peripheral film and ESR
Evaluation of kidney function, serum calcium, CRP, β2
microglobulin, LDH, uric acid levels and liver function tests
Protein electrophoresis and paraprotein quantification
Quantitative analysis of normal immunoglobulins,
24-hours urine collection for light chain (Bence Jones protein)
excretion, coagulation screen
Bone marrow aspiration and trephine biopsy for morphology,
immunophenotyping (CD138, CD79a, kappa, lambda, CD20)
and cytogenetic
Radiological Tests

microglobulin level in the blood to increase. Pretreatment values of β2 microglobulin are thus useful
in confirming tumor mass grade, and in assessing
response to chemotherapy; marked reductions
following chemotherapy correlated well with the
onset of remission. The serum β2 microglobulin
level is one of the prognostic factors incorporated
into the International staging system. Patients with
high values have inferior survival.
The following levels of β2 microglobulin correlate
with stages of multiple myeloma:
Stage I multiple myeloma
l
l

Stage II multiple myeloma
l

Complete skeletal survey
Computerised tomography (CT)

Magnetic resonance imaging (MRI)
(also known as β2M) is a component of MHC class
I molecules, which are present on all white blood
cells (including plasma cells). In humans, the β2
microglobulin protein
is encoded by the β2
microglobulin gene
(Fig. 2). Normal
urinary excretion
of β2 microglobulin
is less than 370
micrograms per
24 hours. Elevated
serum concentration
in the presence of
normal glomerular
filtration rate
suggests increased
β2 microglobulin
production or release,
which is seen in
Fig. 2. Structure of MHC class I β2
microglobulin
lymphoproliferative
diseases such as
multiple myeloma.
The increase is seen in cancers involving white
blood cells, but it is more meaningful in newly
diagnosed multiple myeloma patients. Increased
production or destruction of plasma cells causes β2
12

β2 microglobulin level is lower than 3.5 mg/mL
albumin level is 3.5 g/dL or higher

l

β2 microglobulin level is lower than 3.5 mg/mL
and the albumin level is lower than
3.5 g/dl
β2 microglobulin level is between 3.5 and 5.5
mg/mL

Stage III multiple myeloma
l

β2 microglobulin is 5.5 mg/mL or higher.

The prognostic value of serum β2 microglobulin
level in myeloma is probably due to correlation
of levels with tumour burden. High levels are also
associated with renal failure, which carries an
unfavourable prognosis in multiple myeloma. The
reference ranges are shown in Table 2.
Table 2. Reference Ranges for β2 Microglobulin as Reported in
AKU-Laboratory

Group

			
Median

ng/mL
2.5%ile

95%ile

97.5%ile

Males

1,556

604

2,157

2,284

424

Females

1,473

607

2,295

2,454

370

N

β2 microglobulin test is performed by a
chemilumniscent assay in Clinical Laboratory
AKUH. It is done on clotted blood sample of the
patient; however, it can also be performed on
patient’s urine. Urine may be a single collection
or collected throughout a 24 hour time period. The
urine should be refrigerated until it is brought to the
laboratory and must not become acidic.
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Update on Microbiological Diagnosis of Bone
and Joint Disorders
Dr Kauser Jabeen, Dr Salima Qamar
Microbiology

Prosthetic Joint Infections; How to Effectively use the Available
Diagnostic Modalities?
Prosthetic joint infections (PI) are associated with
substantial morbidity and costs; therefore early
and accurate diagnosis is crucial. The clinical
presentation may be non-specific and vary between
different patient populations. Effective use of the
currently available diagnostic modalities for PI
results in improves outcomes. PI occurring within
three months of joint replacement are categorized as
early and 3-12 months after surgery as delayed and
>12 months as late.
A widely accepted case definition for PI includes:
l
purulence around a prosthesis at arthrotomy or
arthroscopy
l
presence of one or more sinus tract 			
communicating with the joint
l
histological features of infection
l
isolation of similar organism from at least two
deep culture samples. Isolation of virulent 		
organisms, such as Staphylococcus aureus, 		
Escherichia coli, or Candida spp., in one deep
tissue sample may be considered as significant
to confirm the diagnosis.
Gram positive organisms, especially Staphylococci
(commensal skin organisms), are most commonly
involved and in early infection, pathogens are usually
more virulent (for example, Staphylococcus aureus),
whereas more indolent organisms predominate later

on (for example, coagulase negative staphylococci,
Propionibacterium acnes) (Table 1).
Laboratory Investigations
Detection of inflammatory markers:
Baseline blood tests for inflammatory markers
including C reactive protein (CRP), erythrocyte
sedimentation rate (ESR), leukocyte count should be
performed for any suspected case. These parameters
may be elevated up to two weeks after surgery
and cannot be relied upon in early infection. Serial
measurements of these markers are recommended
and persistently or progressively high inflammatory
markers most likely reflect infection. It is important
to note however, that a normal result does not exclude
joint infection especially if the pathogen is of low
virulence.
Cultures:
Blood for culture should be taken in every case
before starting antibiotics as even a single dose is
known to decrease the diagnostic yield. In most cases
however, it is difficult to take deep cultures before
starting antibiotics in patients with systemic sepsis or
rapidly evolving local infection.

Types: PJI can either be acute, chronic or secondary to hematogenous seeding.
Etiologies of Prosthetic Joint Infection
Type of Infection

Etiology

Time of Onset

Early Postoperative
Infection (<3 weeks)

S. aureus
B-hemolytic Strep
Gram-negatives

Symptoms within days to
weeks of surgery

Chronic Infection
(>3weeks)

Coagulase-negative Staph
Corynebacteria
Gram-negatives

Symptoms several months
to 2 years after prosthesis
placement

Hematogenous seeding

Within days of inciting event
Inciting event from prior
infection in other area of the body

Superficial swabs should not
be collected as they most likely
reflect colonising flora and
results must
therefore be interpreted with
caution. Deep samples of
synovial fluid and tissue taken
during arthrotomy/arthroscopy, or
by joint aspiration are needed for
definitive diagnosis. Organisms
should be identified accurately
as treatment options differ for
different organisms (Fig.1 and Fig.
13
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2). Identification of similar organisms from at least
three culture samples is highly predictive of infection
and to increase sensitivity and specificity multiple

Fig. 2. Photomicrograph on the left showing Gram stain of Propionibacterium species; this organisms requires anaerobic conditions
Fig. 1. Coagulase test that is required to differentiate between Staphylococcus
aureus and other Staphylococcus species; two most common organisms responsible for prosthetic joint infections. Upper tube is coagulase positive confirming
the identity of this organisms as Staphylococcus aureus

(five to six) samples should be sent for culture (Box 1).
Organisms associated with prosthetic-joint infection
usually form biofilms thus culture of prosthesis by
vortexing and sonication than conventional periprosthetic tissue culture is more sensitive and specific
especially in patients with prior antibiotic treatment.
Cultures should also be held for longer duration if fungi
or mycobacteria are suspected as causative organisms.

Other diagnostic modalities:
Apart from culture histopathology is an essential
adjunct to microbiology in the diagnosis of infection.
An elevated white cell count and neutrophil differential
of the synovial fluid are also suggestive of infection.
Serial plain radiographs may help in detecting
loosening or bone loss in chronic PI. Ultrasound should
be performed to confirm effusion and to facilitate
aseptic aspiration. Computed tomography and magnetic
resonance imaging may be useful in the evaluation of
complex cases, but metal inserts interfere with these
tests, and abnormalities may be non-specific.

Box 1. Recommendations to improve yield of cultures for diagnosis of PJIs
l
Intraoperative histopathological examination of periprosthetic tissue obtained during surgery
l
At least 3 and optimally 5 or 6 periprosthetic intraoperative tissue samples or the explanted prosthesis
l
Withholding antimicrobial therapy for at least 2 weeks prior to collection of samples

Bone and Joint Infections: Laboratory Diagnosis
Bone and joint infections occur as a result of
haematogenous seeding, contiguous spread of
infection to bone from adjacent soft tissues, or direct
inoculation of infection as a result of trauma or surgery.
Haematogenous spread is more common in children
while contiguous spread is commoner in adults.
Contiguous infection may be either polymicrobial
or monomicrobial while haematogenous infection
is usually monomicrobial. Staphylococcus aureus,
coagulase-negative staphylococci, and aerobic gramnegative bacilli are the most common organisms; less
common pathogens include streptococci, enterococci,
fastidious gram negative organisms and anaerobes.
Mycobacteria, Brucella spp. and fungi have also been
reported in appropriate endemic and clinical settings.
Diagnosis; General Considerations
Cultures: Several factors should be considered while
14

investigating for the diagnosis of these infections.
The most important factor is specimen collection as
it is extremely important to prevent contamination
by normal flora. The samples should be collected as
tissue or fluid rather than swabs because:
l
l
l
l
l

they are more likely than tissue or fluid to be
contaminated
the amount sent for culture is often insufficient
they may inhibit the growth of certain pathogens
fastidious organisms survive less well in 		
swabs than in aspirated fluid or pus
bacteria may adhere to swabs and give a 		
false-negative microscopy result

Ideally, culture specimens should be taken before
antibiotics are commenced. In practice, however,
empirical antibiotics may be commenced before
culture specimens are taken.
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Bone and Joint Infections: Laboratory Diagnosis
If Mycobacteria or fungi are suspected as
etiologic agents; specimens should be sent for
mycobacterial and fungal culture in addition to
culture for routine organisms.
Histopathology: Histopathology and cytology not
only provide rapid results than culture but also
guide in assessing the significance of cultures.
However the tissue Gram stain is an insensitive
test for detecting bacteria as fixing and processing
including chemical decalcification, adversely
affects the Gram stain characteristics.
Nucleic acid amplification tests: There is little
published information regarding the role of nucleic
acid amplification based methods for skin, bone, joint,
and soft-tissue infections. Therefore, routine use of
nucleic acid amplification is not recommended for the
diagnosis of these infections. Although these techniques
may prove useful in selected cases where fastidious
organisms are suspected as cause of infection.
Bone Infections
Close communication between clinician, radiologist
and pathologist/microbiologist is required for optimum
diagnosis. Excisional bone biopsy is required in cases
in which clinical and radiographic features are not
diagnostic. In all cases however, culture is essential for
identification and antimicrobial susceptibility testing.
For that an adequate amount of tissue should be sent to
the microbiology laboratory. For chronic osteomyelitis,
culture of an infected bone specimen is necessary
to establish the diagnosis. Blood culture should also
be sent to aid the diagnosis if the patient is septic. A
positive culture precludes the need for more invasive
procedures if the organism isolated from blood is a
likely pathogen to cause osteomyelitis.

Serial measurements of serum C-reactive protein
levels and erythrocyte sedimentation rates are also
commonly used to monitor response to therapy. The
CRP is a more sensitive parameter than the ESR.
Joint Infections
Synovial fluid analysis is useful in establishing
diagnosis and presence of pus suggest the
possibility of infection (Fig. 2). Joint fluid

Fig. 2. Pus sample aspirated from infected knee joint highly suggestive of
infection. Photomicrograph on the right is showing Gram stain of same
sample revealing numerous pus cells and Gram positive cocci in clusters

should be cultured for both aerobic and anaerobic
bacteria. Blood culture bottles should not be
used to culture joint fluid as they have not been
evaluated for yield for culturing joint fluid (Fig.
3). Fluid aspirated from joints should be collected
aseptically, transferred to a sterile container (or

Cultures of superficial wounds and sinus tracts are
of no value because the results do not correlate
reliably with the pathogen in the underlying bone
except if Staphylococcus aureus or Salmonella spp
are isolated (Fig. 1).
Fig. 3. Blood culture bottles should not be used to culture joint fluid;
fluid aspirated should be transferred to a sterile container

Fig. 1. Swabs from superficial wounds and sinus tract should not be sent
as the organisms isolated do not correlate with the pathogen in bone

left in the syringe), and sent immediately to the
laboratory. Cultures for Neisseria gonorrhoeae
should be transported immediately to the
laboratory. Specimens to be submitted for
mycobacterial culture do not require special
handling.
15
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Mycetoma: Microbiological Diagnosis
Mycetoma is a chronic inflammation of skin
and subcutaneous tissue caused by either
fungi (eumycetoma) or filamentous bacteria
(actinomycetoma). This infection most commonly
presents as a progressive, subcutaneous swelling with
development of multiple nodules. These nodules later
develop into sinuses with discharging grains (Fig. 1).

Fig. 2. Discharging grain from a case of mycetoma

cultures as the specimens may become contaminated
with bacteria or fungi from skin or sinus tracts. The
superficial material from sinus tracts should never be
sent for culture as it will likely grow mixed flora that
does not represent the actual cause of infection.
Fig. 1. Mycetoma of the foot

As the disease progresses involvement of bones
and in advanced cases osteoporosis and bone
destruction can occur. The organisms responsible
for mycetoma are present in the soil and enter
the subcutaneous tissue by traumatic inoculation.
This infection is mainly seen in tropical regions
and Pakistan is one of the endemic countries.
Mycetoma commonly affects adults aged 20 to 40
years, predominantly males. The foot is the most
commonly affected site (80 per cent of the cases).
Diagnosis
Diagnosis is usually determined clinically; however
radiology is required to assess the extent of
spread and involvement of bone and joints. Visual
examination of colour of discharging grains is
crucial for identification of possible etiologic agent
(Fig. 2). In addition to that microscopic examination
after crushing the grains between two slides should
be performed to visualise fungal or bacterial
elements (Table 1). Specimen should also be cultured
for fungi and aerobic actinomycetes (Fig. 3). If
granules are not present, an excisional biopsy for
culture and histopathology or cytology is essential.
Histopathology is also important for correlation with
16

Fig. 3. Culture plate and photomicrograph showing Madurella spp.;
commonest agent of eumycetoma
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Table 1. Common Etiologic Agents of Mycetoma
Etiologic Agents

Colour of the Grains

Eumycetoma Species
Madurella mycetomatis

Black

Madurella grisea

Black

Fusarium spp

White

Acremonium spp

White

Actinomycetoma Species
Nocardia brasiliensis

White

Nocardia asteroides

White

Streptomyces somaliensis

White

Actinomadura madurae

White

Actinomadura pelletieri

Red

Microbiological Diagnosis of Diabetic Foot
Infections
Dr Tazeen Fatima
Microbiology

Diabetic foot infection (DFI) is a frequent clinical
problem. DFIs typically begin in a wound, most often
a neuropathic ulceration or traumatic wound.
The presence of infection is defined by the presence
of more than two signs of inflammation or purulence
or secondary signs (Table 1). Most DFIs are
polymicrobial with Staphylococcus aureus and beta
hemolytic streptococci the most common causes
of infection (Table 1). Gram-negative bacilli are
commonly seen in chronic wounds or in those
patients who have received prolonged prior antibiotic
treatment. Anaerobes may be co-pathogens in
ischemic or necrotic wounds.
Severity
Infections are classified into mild (superficial),
moderate (deeper or more extensive), or severe
(accompanied by systemic signs). This classification
system helps to direct the management of patient,
requirement of imaging procedures, surgical
interventions or amputation. Accurate and timely
diagnosis and proper management is crucial to avoid
unnecessary amputations, morbidity and mortality.

l

Sample collection
Microbiological cultures play an inevitable role in
management of DFIs. Whenever there is suspicion
of infection, appropriately obtained specimens for
culture prior to starting empiric antibiotic therapy
should be sent as therapy may be for a prolonged
duration. Specimen from deep tissue is obtained
by curettage or scraping of tissue from the ulcer
base using a dermal curette or sterile scalpel blade
after the wound is properly cleansed and debrided.
Aspirate and purulent secretions collected using a
sterile needle can also be used. Swab specimens
should be avoided as results are less accurate.
Collected specimens should be
immediately sent in a sterile container and
appropriate transport media to microbiology lab.

l

Management and follow-up
Clinically uninfected wounds do not require
antibiotic therapy. Empiric antibiotic therapy should
only be commenced when there is suspicion of
infection: it should target the likely etiologic agent.
A combined surgical and medical approach, with

l

17
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spectrum parenteral empiric antibiotic therapy with
gram positive,
Clinical Signs of Infected Diabetic Foot
anti-pseudomonal
and anaerobic
Redness, warmth, swelling, tenderness, or pain
Inflammatory signs (>2)
Purulent secretions
coverage is
Non-purulent secretions, discolored granulation tissue,
Secondary signs
recommended.
undermining of wound edges, foul odor
Definitive therapy
Positive probe-to-bone (PTB) test, ulceration for >30 days,
Other signs
should be based
recurrence, peripheral vascular disease or a previous lower limb
on the results of
amputation and loss of protective sensation
Fever, tachycardia, hypotension, and metabolic abnormalities
Systemic signs of infection
an appropriately
(acidosis, dysglycemia, electrolyte abnormalities, worsening
obtained culture
azotemia), and deranged laboratory markers (leukocytosis,
and sensitivity
elevated ESR, CRP or procalcitonin)
testing of a wound
Etiology (Mostly Polymicrobial)
specimen as well
as the patient’s
Staphylococcus aureus (most common), beta-hemolytic strepGram positive
clinical response
tococci (groups A, F, B, C, G), enterococci, coagulase negative
to the empiric
staphylococcus (especially with osteomyelitis), corynebacteria
regimen. Bony
Pseudomonas aeruginosa, Enterobacteriaceae (E.coli, Klebsiella
Gram negative
abnormalities
and Enterobacter species, Proteae), Aeromonas species etc.
(deformity,
Peptostreptococcus species, Bacteroides species (fragilis group),
Anaerobes
destruction, soft
Prevotella species and Clostridia
tissue gas) should
Mucoraceous (Rhizopus, Mucor, Absidia species etc.), Fusarium
Fungal (rare)
be ruled out by
species
plain radiographs
or MRI scans of
the
affected
foot.
The
therapy
should
be at least 4
either oral or parenteral antibiotics, is recommended
weeks
when
there
is
accompanying
osteomyelitis
according to severity of the lesion. Per oral coverage
unless all infected tissue has been resected. A close
for aerobic gram-positive cocci (GPC) is sufficient
follow-up of wound and limb condition is necessary
for one - two weeks for mild to moderate infections
to identify when re-culturing and re-debridement is
in patients without recent antibiotic exposure. For
required.
more severe infections, two – three weeks of broadTable 1. Diagnosis of Diabetic Foot Infections

Classification of Tumours of Bone: an Update
Based on the 2013 World Health Organization
Classification of Tumors of Soft Tissue and Bone
Dr Nasir Ud Din
Histopathology

Introduction
The 4th edition of World Health Organization
(WHO) Classification of Tumours of Soft Tissue
and Bone was published in 2013 almost 11 years
after the prior volume of 2002. Many changes
have taken place in bone tumor classification
during this period predominantly based on the
identification of new genetic findings in different
tumor types. Also, several new morphologically
distinct tumor types have been described, often
18

along with their novel genetic changes. The
advances in classifying and understanding the
pathogenesis of bone Tumours based on the
correlation of histologic and genetic findings
have been particularly significant in the field of
bone oncopathology, perhaps more so than in
many other areas of pathology, with the exception
of hematolymphoid neoplasia. Although many
interesting molecular genetic findings have
been described in bone tumours, this article will
focus on changes in the classification of bone
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sarcomas as well as bone tumours of intermediate
biologic potential (ie, locally aggressive or rarely
metastasizing tumours), new molecular insights
into these tumours, and associated surgical and

clinical implications. The changes are reviewed
according to the categorization of Tumours in the
WHO volume. These changes, along with those in
bone Tumours, are summarized in Table 1.

Table 1. WHO Classification of Tumours of Bone
CHONDROGENIC TUMOURS
Benign
Osteochondroma
Chondroma
Enchondroma
Periosteal chondroma
Osteochondromyxoma
Subungual exostosis
Bizzare parosteal osteochondromatous proliferation
Synovial chondromatosis
Intermediate (locally aggressive)
Chondromyxoid fibroma
Atypical cartilage tumour/Chondrosarcoma grade I
Intermediate (rarely metastasizing)
Chondroblastoma
Malignant
Chondrosarcoma
Grade II, grade III
Dedifferentiated chondrosarcoma
Mesenchymal chondrosarcoma
Clear cell chondrosarcoma
OSTEOGENIC TUMOURS
Benign
Osteoma
Osteoid osteoma
Intermediate (locally aggressive)
Osteoblastoma
Malignant
Low –grade central osteosarcoma
Conventional osteosarcoma
Chondroblastic osteosarcoma
Fibroblastic osteosarcoma
Osteoblastic osteosarcoma
Telangiectatic osteosarcoma
Small cell osteosarcoma
Secondary osteosarcoma
Parosteal osteosarcoma
Periosteal osteosarcoma
High grade surface osteosarcoma
FIBROGENIC TUMOURS
Intermediate (locally aggressive)
Desmoplastic fibroma of bone
Malignant
Fibrosarcoma of bone
FIBROHISTIOCYTIC TUMOURS
Benign fibrous histiocytoma/Non-ossifying
fibroma
HAEMATOPOIETIC NEOPLASMS
Malignant
Plasma cell myeloma
Solitary plasmacytoma of bone
Primary non-Hodgkin lymphoma of bone

OSTEOCLASTIC GIANT CELL RICH TUMOURS
Benign
Giant cell lesion of the small bones
Intermediate (locally aggressive, rarely metastasizing)
Giant cell tumour of bone
Malignant
Malignancy in giant cell tumor of bone
NOTOCHORDAL TUMOURS
Benign
Benign notochordal tumour
Malignant
Chordoma
VASCULAR TUMOURS
Benign
Haemangioma
Intermediate (locally aggressive, rarely metastasizing)
Epithelioid hemangioma
Malignant
Epithelioid hemangioendothelioma
Angiosarcoma
MYOGENIC TUMOURS
Benign
Leiomyoma of bone
Malignant
Leiomyosarcoma of bone
LIPOGENIC TUMOURS
Benign
Lipoma of bone
Malignant
Liposarcoma of bone
TUMOURS OF UNDEFINED NEOPLASTIC NATURE
Benign
Simple bone cyst
Fibrous dysplasia
Osteofibrous dysplasia
Chondromesenchymal hamartoma
Rosai-Dorfman disease
Intermediate (locally aggressive)
Aneurysmal bone cyst
Langerhans cell histiocytosis
Erdheim-Chester disease
MISCELLANEOUS TUMOURS
Ewing sarcoma
Adamantinoma
Undifferentiated high grade pleomorphic sarcoma of bone

19
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Chondrogenic Tumours

Fibrogenic Tumours

Osteochondromyxoma is a new addition to this
category, which is a benign but locally aggressive
tumour exhibiting both osteoid and chondroid
production. This rare tumor arises in approximately
one percent of patients with Carney complex. Sites
of involvement include the tibia and sinonasal bones,
and destructive growth with extension into soft tissue
can occur. Disease recurrence is more likely at sites
where complete resection is difficult; metastases have
not been reported.

The definition of “fibrosarcoma of bone” is
clarified as an intermediate- to high-grade spindle
cell malignant neoplasm that lacks significant
pleomorphism and lacks any line of differentiation
other than fibroblastic. This clarification addresses
several issues. First, a fascicular or “herringbone”
pattern of growth may be observed in many different
tumor types that can be classified in other specific
diagnostic categories. Second, this pattern of growth
may also be seen in otherwise unclassified highgrade pleomorphic sarcomas, and if significant
pleomorphism is present the tumor is best classified
as the latter. Fibrosarcoma of bone is therefore a
diagnosis of exclusion, and the diagnosis cannot
be made on limited biopsy samples, because
thorough sampling is needed to exclude other lines
of differentiation. The incidence of fibrosarcoma is
likely much less than the five percent documented in
the prior WHO classification.

Chondrosarcoma is now separated into two groups,
with grade one distinguished from cases of grade
two and grade three chondrosarcoma. In addition,
the synonym “atypical cartilaginous tumor” was
introduced for “grade one chondrosarcoma.” These
Tumours are locally aggressive but metastasize
only extremely rarely; the five year survival rate
is 83 percent, with death from disease occurring
due to uncontrollable tumor growth, especially in
patients with pelvic Tumours. Curettage/simple
excision alone is considered adequate treatment. For
those Tumours that recur, approximately 10 percent
demonstrate an increase in cellularity warranting
a change in grade. In contrast, grade two and three
chondrosarcomas frequently metastasize and have
a five year survival rate of 53 percent; en bloc
resection is recommended for this group of patients.
Tumours should be graded based on the area of
highest histologic grade in cases in which variable
histologic grades exist within the same tumor.
Osteogenic Tumours
The only change in the classification of osteogenic
Tumours is the incorporation of secondary
osteosarcoma into the category of conventional
osteosarcoma for descriptive purposes. Conventional
osteosarcoma is subclassified based on histologic
features (e.g, osteoblastic, chondroblastic), but
there remains no relationship between the subtype
of conventional osteosarcoma and treatment and
prognosis, in contrast to other types of osteosarcoma.
Amplification of mouse double minute two homolog
(MDM2) and cyclin-dependent kinase 4 (CDK4)
have now been well documented in low-grade
central osteosarcoma and parosteal osteosarcoma,
and immunohistochemistry for these two markers
can be a helpful tool, especially in those cases that
have undergone dedifferentiation to a high-grade
osteosarcoma and in which recognition of the precursor
low-grade lesion is difficult clinically or pathologically.
20

Fibrohistiocytic Tumours
Similar to soft tissue tumor classification, the category
of “malignant fibrous histiocytoma” of bone has been
removed from the 2013 classification of bone Tumours.
Ewing Sarcoma
The term PNET has been removed as a synonym
for Ewing sarcoma. Of round cell sarcomas of
bone that do not fulfill criteria for Ewing sarcoma,
two genetically distinct groups of Tumours have
been recognized that harbor CIC-DUX4 or BCORCCNB3 fusion genes.
Osteoclastic Giant Cell-Rich Tumours
In this category, “giant cell tumor of bone” is now
separated from “giant cell lesion of the small bones.”
Giant cell lesion of the small bones is a very rare
tumor-like lesion that arises in the small bones
of the hands and feet and commonly recurs after
initial curettage, but is almost always cured after the
second excision. Giant cell tumor of bone is a locally
aggressive neoplasm that may very rarely metastasize
or undergo malignant transformation into a highgrade sarcoma, either de novo or after radiotherapy.
Notochordal Tumours
Benign notochordal cell tumor was added to this
category, which previously only included chordoma.
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This benign tumor may represent persistent
notochord rather than a true neoplastic proliferation;
benign notochordal cell tumor arises at the base of
skull, vertebral bodies, and sacrococcygeal bones and
is usually an incidental finding.
Vascular Tumours
Hemangioma has been separated from epithelioid
hemangioma, a recently characterized neoplasm
composed of small vessels lined by epithelioid
endothelial cells. Epithelioid hemangioma most
often arises in long tubular bones, followed by flat
bones and vertebrae. In contrast to conventional
hemangioma, epithelioid hemangioma is locally
aggressive: recurrence occurs in approximately 10
percent of cases. Treatment consists primarily of
curettage, and less often local resection. Epithelioid
hemangioma should also be distinguished from
epithelioid hemangioendothelioma (EHE), which is
classified as a malignant neoplasm that demonstrates
endothelial differentiation, and the mainstay of
treatment is wide resection. The mortality rate is
approximately 20 percent and histologic features
do not predict the development of metastases.
Recurrent fusion genes have been identified in EHE,
namely WWTR1-CAMTA1 and YAP1-TFE3. These
fusion genes are not present in angiosarcoma or
benign vascular Tumours.

Undifferentiated High-Grade Pleomorphic Sarcoma
High-grade pleomorphic malignant Tumours that
lack a specific line of differentiation are classified
as “undifferentiated high-grade pleomorphic
sarcoma.” This diagnosis is one of exclusion, and
thorough sampling is needed to exclude osteoid
deposition, which would necessitate a diagnosis of
osteosarcoma, as well as other histologic features
that may suggest a specific diagnosis.Tumours in this
category have a metastatic rate of at least 50 percent.
Treatment generally involves neoadjuvant therapy
followed by wide excision for potentially resectable
lesions. Similar to osteosarcoma, the degree of
tumor necrosis after neoadjuvant chemotherapy is an
important prognostic factor.
Conclusions
Since the publication of the prior WHO
Classification of Tumours of Soft Tissue and Bone 11
years ago, new clinicopathologic and genetic features
of many bone Tumours have been characterized,
which has led to more reproducible classifications
of these Tumours and therefore more effective
treatment stratification. This has also allowed
obsolete tumor types such as the so called malignant
fibrous histiocytoma to be removed from the 2013
WHO classification. In addition, several new entities
have been included for the first time in this volume.

Recent Developments in Benign Bone Tumours
Dr Nasir Ud Din
Histopathology

Introduction

medical management have been developed.

Benign tumours of bone frequently pose a diagnostic
challenge for general surgical pathologists.
Careful clinical and radiological correlation is required
for accurate diagnosis. Significant recent advances
in some benign bone tumours have occurred at the
molecular and cytogenetic level, which have provided
a better understanding of the pathophysiology of
certain tumours. It has also provided an important aid
in the diagnostic workup and differential diagnosis of
some bone lesions demonstrating overlapping clinical
and pathologic features. Prognostic and therapeutic
applications of these findings are the future directions.
For the treatment of certain benign bone tumours,
newer less invasive therapeutic techniques and

Osteoid Osteoma
Osteoid osteoma is a benign bone-forming tumour
commonly arises in the cortex of diaphysis or
metaphysis of long bones (femur and tibia) or
posterior vertebral elements in second and third
decades of life. The typical presentation is nocturnal
pain relieved by nonsteroidal anti-inflammatory drugs
(NSAIDs). The pain is caused by local production of
high levels of prostaglandin E2, which is mediated by
cyclooxygenases (COX-1 and COX-2).
Radiographically, osteoid osteoma classically
presents as an area of cortical thickening and
21
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sclerosis containing a lucent focus “nidus” of less
than two cm. Histologically, the nidus consists of
an interlacing network of woven bone trabeculae
with variable mineralization in a loose fibrovascular
stroma (Figure 1). The bone trabeculae are rimmed
by osteoblasts, with scattered osteoclastic-type
multinucleated giant cells.

oval, well-demarcated, lytic lesions surrounded by a
rim of reactive bone. Histologically, osteoblastoma
is similar or identical to the nidus of an osteoid
osteoma. It is composed of inter anastomosing
trabeculae of woven bone in a loose fibrovascular
stroma with conspicuous osteoblastic rimming and
abundant osteoclasts (Figure 2). The lesion is sharply
demarcated from the adjacent bone and is often
surrounded by a rim of reactive bone. Osteoblastoma
does not permeate cortical and host bone or invade
into soft tissue.

Figure 1. Osteoid osteoma exhibiting interconnecting bone trabeculae with
osteoblastic rimming and loose fibrovascular stroma

Recent development in osteoid osteoma is in its
treatment, to control pain. Minimally invasive
techniques have been developed include CTguided core drill excision, percutaneous
radiofrequency ablation (RFA), cryoablation, or
laser photocoagulation. Radiofrequency ablation has
gained great popularity because of its advantages
over traditional surgery. It is minimally invasive,
safe, and highly effective (pain relief within 24 hour to
one week after treatment). It is useful in the treatment
of lesions in atypical or technically challenging
locations (intra-articular, spinal, or short bone lesions).
Tissue necrosis is induced by thermal coagulation
through insertion of an electrode into the lesion. The
main advantages of the procedure include minimal
bone loss and structural weakening, less morbidity
(infections), shorter anesthesia, minimal restriction of
physical activity, short hospitalization and recovery
time (usually a few hours), and lower cost.
Osteoblastoma
Osteoblastoma is a rare, benign bone neoplasm
which is histologically and clinically similar to
osteoid osteoma but has a potential for progressive
growth and local recurrence. It is characterized
by larger size (>2 cm) and dull pain that may not
be relieved by NSAIDs. The peak incidence is in
the second decade of life and it is more common
in males. Osteoblastoma has predilection for the
axial skeleton (posterior vertebral elements) but
also occurs in the appendicular long bones and the
mandible. Most cases are radiographically round to
22

Figure 2. Osteoblastoma showing interconnecting bone trabeculae with
osteoblastic rimming and loose fibrovascular stroma and few osteoclasts

A unique three-way translocation involving
chromosomes 1, 2, and 14 [t(1;2;14)(q42;q13;q24)]
and rearrangement of 1q42 have been reported in
osteoblastoma.
An epithelioid variant of osteoblastoma has been
described with a tendency to local recurrence but no
metastatic potential has been described. Conventional
osteoblastoma has a good prognosis with a local
recurrence rate of 16 percent – 20 percent. The
tumors are treated with surgical removal either by
curettage or by en bloc resection.
Fibrous Dysplasia
Fibrous dysplasia (FD) is a dysplastic anomaly of
bone forming mesenchymal tissue. There is focal or
multifocal inability to produce lamellar bone, with
an arrest at the level of woven bone. This leads to
the formation of a mass of immature isolated woven
bone trabeculae enmeshed in dysplastic fibrous
tissue which never complete the remodeling process.
Consequently, there is substantial loss of mechanical
strength, pain, deformity, and pathologic fractures.
Most lesions are diagnosed before the age of 30
years. It may be monostotic or polyostotic. The
monostotic form represents 60 percent or more
of all patients with the disease and it is usually
asymptomatic. Fibrous dysplasia may develop in
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practically any bone (craniofacial bones, femur,
tibia, and ribs are preferred sites). Radiologically the
lesions are lytic and expansile, with thinning of the
adjacent cortices and internal “ground glass” pattern
of opacification caused by mineralization of the
woven bone trabeculae.
Histologically, FD is composed of cytologically
bland spindle cells with interspersed slender
trabeculae of woven bone devoid of prominent
rimming osteoblasts or osteoclasts (Figure 3).

diagnosis in difficult cases. FGF-23 can be elevated
in patients with FD, leading to renal phosphate
wasting and hypophosphatemia. The presence of
structural alterations involving chromosomes 3, 8,
10, 12, and 15 suggests that FD may be a neoplastic
condition with a predisposition to somatic mutations
of bone-forming mesenchymal tissue.
Curettage with bone grafting is the traditional
treatment for FD. However, there have been changes
over the past decades with the introduction of
medical management with bisphosphonates (mainly
pamidronate), which are potent inhibitors of bone
resorption and have a lasting effect on bone turnover.
Radiographic improvement of the lesions, decrease
in bone pain, and biochemical markers of bone
remodeling have been observed with this treatment.
Surgery is indicated for correction of deformities and
prevention of impending fractures.
Osteochondroma

Figure 3. Fibrous dysplasia composed of irregular woven bone
trabeculae with interspersed fibrous stroma

Recent developments in FD involve new insights
into its pathophysiology with the description of a
gene mutation and biological pathways involved.
It is now regarded as a genetic, non-inheritable
disease caused by missense mutations occurring
post zygotically in the gene coding for the alpha
subunit of the stimulatory G protein Gs, in the
GNAS complex locus in chromosome 20q13
(gsp mutation). The resulting proteins display
reduced GTPase activity, with increased adenylyl
cyclase activation. The mutated cells constitutively
generate high levels of cAMP and have a high
proliferation rate. Activation of the Gs alpha/PKA/
CREB pathway induces c-fos overexpression in
mesenchymal precursor cells, which interferes with
normal osteoblast differentiation. It has also been
suggested that increased cAMP may down regulate
the osteoblastic transcription factor Runx two,
contributing to abnormal osteoblastic differentiation.
This is the basis for the histologic hallmark of
extensive proliferation of fibrous tissue produced by
the abnormally differentiated preosteoblastic cells.
Another downstream effect of increased cAMP is
increased levels of interleukin six, which in turn
may be responsible for osteoclast recruitment and
activation and consequently bone resorption. It is
now possible to test for the genetic mutation in
peripheral blood samples by genetic amplification
techniques such as PCR, which may confirm the

Osteochondroma is a relatively common benign bone
tumour. It is more common in males in the first and
second decades of life and occurs in bones formed by
endochondral ossification. The metaphyses of long
bones are the preferred site (distal femur, proximal
tibia, and proximal humerus) but it may arise in flat
bones like the ilium and scapula. Most lesions are
solitary but approximately 15 percent of patients
have multiple lesions. Multiple osteochondromatosis
or hereditary multiple osteochondromas (HMO) is
an autosomal dominant inherited condition where
multiple osteochondromas develop in several bones,
leading to significant deformity.
Histologically, the cap resembles an epiphyseal plate,
particularly at its base. All osteochondromas usually
stop growing when the parent growth plates close.
The most significant recent advances are related
to the identification of the gene mutations
that characterize HMO and their link to its
pathophysiology. Mutations of the EXT1 (8q24.1),
EXT2 (11p11-12), and the recently described EXT3
(19p) tumor suppressor genes are associated with this
condition. Loss of genetic material from the long arm
of chromosome eight is the distinctive cytogenetic
alteration of osteochondroma. It is hypothesized that
EXT mutations affect the signaling pathways of the
growth plate chondrocytes. Indian hedgehog (IHH)
and parathyroid hormone-like hormone (PTHLH)
function in a negative feedback loop to inhibit the
differentiation of proliferating chondrocytes in the
growth plate. Prehypertrophic chondrocytes express
23
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IHH, which stimulates perichondrial cells to produce
PTHLH. PTHLH in turn inhibits both growth plate
chondrocyte differentiation and the expression of
IHH. PTHLH binds to proliferating chondrocytes,
inhibiting differentiation and apoptosis through
induction of Bcl-2 production.EXT1 and EXT2
are transmembrane glycoproteins involved in the
synthesis of heparin sulfate proteoglycans (HSPGs).
HSPGs bind to IHH ligands in the extracellular
environment, which controls their diffusion.
Mutations involving EXT genes lead to abnormal
processing of HSPGs and their accumulation in
the cytoplasm of chondrocytes. Defective HSPG
production associated with EXT mutations causes a
disruption in this signaling pathway, which in turn
causes aberrant maturation and bone growth within
the proliferating cartilage.
Treatment is reserved for symptomatic cases.
Complete excision of the osteochondroma including
the perichondrium is usually curative.
Malignant transformation to chondrosarcoma
has been reported in 1 percent of solitary
osteochondromas and 1 percent – 3 percent of
multiple osteochondromas. Most cases are low-grade
chondrosarcomas.
Enchondroma
Enchondroma is a benign intramedullary mass of
hyaline cartilage. About 41 percent of the cases
occur in the small bones of the hands and feet. It may
also arise in long tubular bones (proximal humerus,
proximal and distal femur), the ribs, and the spine.
The metaphysis is a preferred location and the
lesion is usually asymptomatic. Radiographically,
enchondroma is well demarcated and radiolucent
with stippled calcification. Expansion and thinning
of the surrounding cortex with endosteal scalloping
may be seen in the small bones.
Histologically, enchondroma is composed of lobules
of hypocellular hyaline cartilage without mitotic
activity or nuclear pleomorphism (Figure 4). It
lacks evidence of permeation of marrow spaces
or entrapment of preexisting bony trabeculae.
The differential diagnosis between enchondroma
and low-grade chondrosarcoma is challenging
and requires careful clinical, radiological, and
histopathological correlation. The treatment of
enchondroma is curettage and bone grafting. Local
recurrence is uncommon. Most enchondromas
have a normal karyotype. Structural abnormalities
of chromosomes 6 and 12 have been described.
In enchondromas, PTHLH signaling is active,
24

Figure 4. Enchonroma composed of lobules of hyaline cartilage encased
by thin rim of reactive bone.

but independent of Indian hedgehog (IHH),
irrespective of the presence or absence of absence
of enchondromatosis. Heterozygous somatic
mutations have been detected in at least 50 percent
of solitary enchondromas and approximately
90 percent of enchondromas from patients with
enchondromatosis.
Chondroblastoma
Chondroblastoma is a benign bone neoplasm with
predilection for the epiphyses of the long bones in
skeletally immature individuals. Most cases occur
during the second decade of life. The proximal and
distal femur, proximal tibia, and proximal humerus
are most commonly affected. Radiographically,
eccentric, well-circumscribed, lytic lesion centered
in the epiphysis with partially sclerotic margins
is seen. Histologically, chondroblastomas are
composed of round to polygonal cells with welldefined cytoplasmic borders. The cytoplasm is
clear to slightly eosinophilic and ovoid nuclei
with longitudinal grooves. Randomly distributed
osteoclast-type giant cells are invariably present.
Linear pericellular calcification (“chicken-wire”) is
characteristic (Figure 5).

Figure 5. Chondroblastoma composed of sheets of polygonal cells with
focal chicken wire calcification.
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Chondroblastomas generally express S-100 protein,
CK8, CK18, and CK19.
Strong expression of the cartilage lineage regulator
Sox9 has been recently demonstrated.
Structural abnormalities of chromosomes 5 and 8
seem to occur frequently in chondroblastoma.
Chondromyxoid Fibroma
Chondromyxoid fibroma (CMF) is one of the least
common bone tumours. The metadiaphysis of the
proximal tibia and the ilium are commonly affected
sites. Radiographically, it appears as an eccentric,
sharply marginated lytic lesion with scalloped
margins and a sclerotic bony rim. Histologically,
the tumor is composed of lobules with loose
myxoid stroma containing spindle- to stellate-shape
cells. The lobules are separated by fibrous septa
containing multinucleated osteoclast- type giant
cells (Figure 6). CMF has a high expression of

skeletally mature individuals (peak incidence is
between ages 20 and 45 years), commonly arises
in the epiphysis of long bones, most commonly
the distal femur, proximal tibia, distal radius,
and proximal humerus. Radiographically, GCT
appears as an epiphyseal, eccentric, and expansile
lytic lesion without significant marginal bony
sclerosis, extending into the adjacent metaphysis.
Histologically, the tumour is composed of
uniformly distributed osteoclast-type giant cells in
a background of mononuclear, round, polygonal,
and spindle cells lacking cytologic atypia (Figure 7).

Figure 7. Giant cell tumor composed of evenly dispersed osteoclast type
giant cells among mononuclear cells.

Figure 6. Chondromyxoid fibroma exhibting a lobulated architecture
composed of spindle cells with peripheral osteoclast type giant cells.

certain cell cycle progression molecules and cellto-cell adhesion molecules such as p16, cyclin D1,
and ALCAM (CD166). These can be assessed by
immunohistochemistry and have been suggested as
an aid in distinguishing CMF from chondrosarcoma.
CMF demonstrates strong expression of the cartilage
lineage regulator S0x9. Chromosome 6 aberrations
is frequent but heterogenous; regions commonly
involved include 6p23-25, 6q12- 15, and 6q23-27.
It has been suggested that these may be helpful in
distinguishing CMF from chondrosarcoma where
rearrangements involving these sites of breakpoint
clustering on chromosome six are uncommon. The
treatment for CMF is curettage and bone grafting.
Recurrence occurs in about 25 percent of cases.
Giant Cell Tumour of Bone
GCT is a benign, locally aggressive neoplasm of

Mitoses are variably seen in the mononuclear cells
and atypical forms are absent. The mononuclear
cells constitute the neoplastic cell population,
whereas the multinucleated giant cells are reactive.
Vascular invasion may be identified in GCT and this
finding does not correlate with the rate of pulmonary
metastases. The tumor frequently invades and
destroys the subchondral bone plate supporting the
articular cartilage. The behavior of a GCT cannot be
predicted from its histopathological features. Local
recurrence occurs in about 20 percent of cases after
curettage. Lung metastases may occur in two percent
of cases and most are clinically indolent. Malignant
transformation may occur at the site of a previously
excised GCT or following irradiation.
Recent studies suggest that the neoplastic mononuclear
cells of GCT are derived from primitive pluripotential
mesenchymal stem cells and exhibit a preosteoblastic
phenotype. They express collagen type I, alkaline
phosphatase, osteocalcin, matrix metalloproteinases,
macrophage colony-stimulating factor, osteoprotegerin,
and receptor activator for nuclear factor kappa B
ligand (RANK-L). The latter is a cytokine belonging
to the tumor necrosis factor family (TNF-alpha)
that is a potent stimulator of osteoclast formation,
differentiation, and maturation. The osteoclast-like
giant cells express RANK receptor and are most
25
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likely derived from recruited monocytes under the
provision of the neoplastic mononuclear cells. RANK-L
expression by the neoplastic mononuclear cells of
GCT is responsible for giant cell formation and bone
resorption. Matrix metalloproteinases (MMP-2 and
MMP-9) are also produced by the mononuclear stromal
cells and may play a role in osteolysis. GCT has been
reported to exhibit strong expression of TP73L gene and
p63 protein in 69 percent – 100 percent of cases.P63 has
been proposed as a useful marker for the diagnosis of
GCT. The characteristic chromosomal aberrations seen
in GCT are telomeric associations. Their significance
is also unclear. Recurrent numeric or unbalanced
structural abnormalities are uncommon.
Treatment of GCT is surgery and curettage with
bone grafting or cementation are most commonly
used. Bisphosphonates have been used as adjuvant
treatment for problematic primary, recurrent, and
metastatic GCT. Bisphosphonates aid in controlling
the osteolysis associated with tumour growth by
reducing osteoclast numbers and inhibiting osteoclastic
resorption. Recent advances in the understanding
of molecular cell signaling in bone remodeling and
osteoclast differentiation and activation have led to
new therapeutic targets, mainly anti RANK-L therapy.
Denosumab is a human monoclonal antibody against
RANK-L that inhibits osteoclast-mediated bone
destruction. Clinical trials are underway with promising
results as an adjuvant treatment to surgery or as sole
treatment in inoperable cases, particularly those with
pulmonary metastases.

Conclusions
The most important advances at the molecular
and cytogenetic level have shed some light on
the pathogenesis of certain tumours such as Gs
alpha mutation in fibrous dysplasia and EXT gene
mutations in osteochondroma. Clonal aberrations
found in these tumours have been proposed as
evidence suggestive of a neoplastic nature. In other
instances, mutational analysis demonstrates specific
gene rearrangements that may be useful in the
differential diagnosis of lesions with clinical and
pathologic similarities such as fibrous dysplasia
and low-grade osteosarcoma, chondromyxoid
fibroma, and chondrosarcoma or GCT and
aneurysmal bone cyst. One of the most significant
recent advances is the identification of the RANK/
RANK-L system of cell signaling, which is the
main regulatory mechanism of osteoclast formation,
activation, and survival. Its role in normal bone
remodeling, metabolic bone disease and tumour
osteolysis has unveiled an important therapeutic
target for the treatment of such conditions with
antibodies directed to RANK-L. It has also helped
us partially understand the molecular and cellular
biology of GCT of bone. RFA and bisphosphonates
are therapeutic modalities that are gaining great
popularity and widespread use by reducing the
invasiveness and morbidity associated with traditional
surgical management and providing treatment
alternatives to inoperable or advanced stage tumours.

Rheumatoid Arthritis: Anti CCP Antibodies
and Rheumatoid Factor
Dr Hafsa Majid
Chemical Pathology

Rheumatoid Arthritis (RA) is the commonest
inflammatory joint disease, affecting nearly one
percent of the adult population worldwide and
0.9-1.98 percent of Pakistani population. Although
the precise etiology of RA remains unknown, there
is strong evidence for autoimmunity since several
autoantibodies are associated with the disease.
It is characterized by multiple deformities and is
associated with considerable morbidity and mortality.
Patients with RA follow a variable disease course
with regard to outcome measures; functional status
26

or radiological assessment of joint damage. Early
identification of patients with RA and, in particular,
those likely to assume a more rapidly destructive
form of disease, is important because of the possible
benefit from early, aggressive intervention with
disease modifying agents. However there is no single
clinical, radiologic, or serologic test that enables a
diagnosis of RA to be made with certainty. As with
other autoimmune diseases, the diagnosis depends
upon the aggregation of characteristic symptoms,
signs, laboratory data, and radiologic findings. The
main clinically useful biologic markers in patients
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course of their disease. The anti-CCP testing offers
certain advantages including:

with RA include rheumatoid factor (RF), anti-cyclic
citrullinated peptide (anti-CCP) antibodies, erythrocyte
sedimentation rate (ESR), and C-reactive protein (CRP).

l

1. Rheumatoid Factor
Rheumatoid factor is the autoantibody directed against
the Fc portion of Immunoglobulin G (IgG). The RF
is a well-established diagnostic and prognostic test
in Rheumatoid Arthritis. High titer RF is relatively
specific for the diagnosis of RA in the context of a
chronic polyarthritis, and often appear many years
before the onset of clinical RA. It was for decades the
sole serologic criterion widely used as the diagnostic
and prognostic markers of RA.
The RF is considered an early marker since its
presence is linked with an increased risk of developing
RA in people with mild arthritic symptoms.
Rheumatoid factor may have some prognostic value
with regard to disease manifestations and activity,
and the severity of joint erosions. A seropositive
RA (ie, RA associated with a positive rheumatoid
factor test) is often associated with more aggressive
joint disease, and is more commonly complicated by
extra-articular manifestations than seronegative RA.
RF also occurs in other diseases, including a variety
of rheumatic disorders, many of which share similar
features, such as symmetric polyarthritis and Nonrheumatic disorders characterized by chronic antigenic
stimulation, shown in Table 1. Rheumatoid factors
have been found in up to four percent of young,
healthy individuals, higher incidence in elderly.

l
l

l

l

l

The sensitivity of anti-CCP antibodies is similar
to that of RF, but specificity is high (90 to 96
percent).
Anti-CCP antibodies predict erosive disease
more effectively in RA patients than RF.
It may also be valuable in identifying those
patients with early RA who are at increased risk
of progressive joint damage.
Anti-CCP testing is a clinically useful tool
in diagnosis or exclusion of RA in patients
with polyarthritis. Anti-CCP may be useful in the
differential diagnosis of early stage RA,
particularly in the ability to distinguish RA from
primary Sjögren’s syndrome or SLE.
Among patients with early oligo- or polyarthritis,
anti-CCP testing appears to be of predictive
value in the RF negative subgroup.
In contrast to RF, anti-CCP antibodies are rarely
present in the serum of patients with HCV
infections.

3. Combination of RF and Anti-CCP Antibodies

Testing for both anti-CCP antibodies and RF may be
better for excluding the diagnosis of RA than testing for
either antibody alone. Those with early arthritis who are
RF or anti-CCP antibody positive are at an increased
risk of developing RA and erosive joint disease, while
those with neither of these markers are less likely to
Table 1: Rheumatoid and non-Rheumatic Diseases Associated with raised RF. develop joint damage. Thus, earlier intervention with
Rheumatic Diseases

Non-Rheumatic Diseases

Rheumatoid arthritis — 26 to 90 %

Indolent or chronic infection e.g., Hepatitis B virus infection

Sjögren’s syndrome — 75 to 95 %

Mixed cryoglobulinemia — 40-100%

Inflammatory or fibrosing pulmonary disorders, such as sarcoidosis.
Hepatitis C especially when accompanied by cryoglobulinemia, 54 to 76% of cases
Malignancy

Systemic lupus erythematosus — 15-35%

Primary biliary cirrhosis

Polymyositis/dermatomyositis — 5-10%

-

Mixed connective tissue disease — 50 to 60%

2. Anti-CCP Antibodies
The aAti-CCP testing is a clinically useful tool
in diagnosis or exclusion of RA in patients with
polyarthritis. Patients with an established diagnosis
of RA who have a positive test for RF, anti-CCP
antibodies, or both are at a higher risk of developing
erosive joint damage and functional impairment. As
a result, such patients should receive anti-rheumatic
therapy that suppresses disease activity early in the

disease modifying antirheumatic drug therapy may
be warranted in those with positive markers, while
symptomatic treatment may be appropriate for those
lacking both RF and anti-CCP antibodies. Diagnoses
other than RA should be considered in patients who
are both RF and anti-CCP antibody negative. Unless
it is demonstrated that there is an intervention that
effectively and safely reduces the risk of developing
RA, there is no role for screening asymptomatic
individuals for either RF or anti-CCP antibodies.
27
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Clinical Utility of Urinary Calcium
Dr Sibtain Ahmed
Chemical Pathology

Calcium (Ca) is a fundamental element necessary
to form electrical gradients across membranes, an
essential cofactor for many enzymes, and the main
constituent in bone. Under normal physiologic
conditions, the concentration of calcium in serum
and in cells is tightly controlled. Calcium exists in
three states in the body; bound to protein, bound
to small anions, and in the free (ionized) state. The
concentration of serum calcium in the ionized state
is regulated by parathyroid hormone (PTH) and 1, 25
dihydroxy vitamin D.
Excretion of Calcium
Circulating calcium is excreted by glomerular
filtration and reabsorbed in the proximal tubules.
Calcium reabsorption in the proximal tubule
is affected by tubular sodium concentration,
whereas PTH induces calcium uptake in the distal
tubule and the collecting duct. Excess calcium is
excreted in the urine and the feces. Urine calcium
levels also reflect dietary intake. In average adult
urine sample collected over 24 hours, 100–300
mg of calcium excretion is considered normal. It
is also important to note that calcium excretion is
heavily influenced by sodium excretion. Lowsodium diets tend to decrease calcium excretion
and vice versa.
Laboratory Indices for Evaluation of Calcium
Excretion
Although a 24-hour collection is best, random
urine calcium measurement can also be performed
to calculate calcium/creatinine ratio or fractional
excretion of calcium (FECa) on urine specimens.
l
24 hour Ca excretion: The reference range for
urine calcium is 100-300 mg/24-hour.
Hypercalciuria is >350 mg/24-hour specimen.
l
Ca: Cr ratio: A normal reference interval for
the urine calcium (mg/dL): urine creatinine
(mg/dL) ratio is <0.14. Values exceeding 0.20
(for men) or 0.57 (for women) are found in 		
patients with hypercalciuria.
l
FECa: Simultaneously 3 - 5 cc of serum is also
required for analysis of Ca and Cr.
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The formula for FECa is as follows: (urine Ca ×
serum Cr) / (serum Ca × urine Cr) × 100
In Familial hypocalciuric hypercalcemia (FHH)
the FECa results are usually ≤0.01.
Clinical Utility of Measuring Ca Excretion
The primary clinical value of urine calcium
measurement is to aid in the differential diagnoses
of patients and direct optimal treatment options
for patients with abnormal serum calcium. Various
conditions associated with abnormal urinary Calcium
levels are enumerated in Table 1.
Table 1: Conditions associated with abnormal Urinary Calcium levels
Hypercalciuria Associated with Hypercalcemia
Primary Hyperparathyroidism
Hypervitaminosis D
Sarcoidosis
Bone metastases
Multiple Myeloma
Corticosteroids
Prolonged immobilization
Paget’s disease
Hypercalciuria with Normocalcemia
Increased Calcium intake
Idiopathic Hypercalciuria
Renal tubule acidosis
X-Linked Hypercalciuria (Dent’s Disease)
Hypercalciuria Associated with Hypocalcemia
Calcium-sensing receptor activating mutation
Hypocalciuria
Hypoparathyroidism
Pseudo-Hypoparathyroidism
Vitamin D Deficiency
Low calcium diet
Familial Hypocalciuric Hypercalcemia
Renal Osteodystrophy
Medications Causing Hypercalcemia
Thiazide Diuretics
Oral Contraceptives
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HLA B-27 at a Glance
Sheeba Parveen
Molecular Pathology

HLA (Human leukocyte antigen) B-27 is class
I surface antigen which is encoded by genes
present on short arm of chromosome 6 (Fig.

such as viruses and bacteria ‘non-self’. HLA
B-27 is strongly associated with the condition
ankylosing spondylitis, which is named due to
the terms ‘Ankylosing’ or fusing together and
‘spondylitis’ or inflammation of bones of spine.
This and other associated inflammatory diseases
are collectively referred to as ‘spondyloarthritis’.
It is uncertain how HLA B-27 causes increase risk
of ankylosing spondylitis.
Researchers speculates that HLA B-27 may
abnormally display to immune system peptides that
trigger arthritis other researchers suggests that joint
inflammation characteristic of this disorder may
result from improper folding of HLA B-27 protein
or the presence of abnormal forms of the protein on
the cell surface.
Ankylosing spondylitis is two to three times more
common in males than in females, and it affects all
age groups including children. The most common
age of onset of symptoms is the second and third
decade of life. The effect of the disease is depicted
in Fig. 1B Symptoms of ankylosing spondylitis
include back pain and stiffness (worst at night and

Fig.1.A. The Organization of HLA Genes on Chromosome 6

1A). The HLA genes are the human versions of
MHC genes that are found in most vertebrates.
The proteins encoded by certain genes are also
known as antigens, as a result of their historic
discovery as a factor in organ transplantation.
The major HLA antigens are essential elements
for immune function. Different classes have
different functions.
The role of HLA B-27 molecules is presentation
of peptides to T-cells. The immune system uses
HLAs to distinguish the body its own proteins
‘self’ from the proteins made by foreign invaders

Fig.1.B. Diagrammatic Representation of the effect of Ankylosing
Spondylitis on the Spine.

in morning), weight loss, feeling unwell, tiredness,
pain and swelling of hips, knee or joints, plantar
fasciitis (pain under heel of foot), aching in chest,
around ribs. It may be associated with psoriatic,
colitic and reactive arthiritis. The complications of
the disease are uveitis (inflammation of eye) and
issues related to heart and lungs.
29
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For molecular diagnosis of ankylosing spondylitis
a venous blood sample is required for the test.
DNA is extracted from blood using the sodium
dodecyl sulphate (SDS)-proteinase K lyses
method and then amplified by conventional
polymerase chain reaction (PCR). Using Sequence
specific primer (HLA-A and HLA–B) primers.
In addition, PCR for the growth hormones (GH
1 and GH 2) genes is used as an internal control.
Amplified product is than analysed by agarose gel
electrophoresis (Fig. 2).
A positive band of 144 kb obtained in the PCR
reaction indicates the presence of the HLA-B27
allele, and based on this the result of the test is
reported as a ‘presence’ or an ‘absence’ of the
HLA B27 allele. An internal control is included
in each PCR reaction to monitor the presence of
PCR inhibitors in the specimen.

Fig. 2. Detection of the HLA B-27 all ele. The picture depicts the presence of DNA on an agarose gel stained with ethi dium bromide. Fluorescent bands indicate the presence of DNA in each lane

Clinical Utility of Serum 1,25OHD Testing
Dr Shabnam Khawaja
Chemical Pathology

Introduction
1, 25 dihydroxyvitamin D (1,25 (OH) 2D) is the
most potent and active vitamin D metabolite. It is
produced in kidney by enzymatic hydroxylation
of 25-hydroxyvitamin D (25(OH) D). Plasma
1,25-dihydroxyvitamin D (1,25(OH)2 D) is tightly
controlled by plasma parathyroid hormone (PTH),
serum calcium, serum phosphate, and fibroblast-like
growth factor 23 (FGF-23)
1, 25(OH)2D alone provides essentially no
information about the nutritional status of vitamin
D. Consequently, 25OHD is the preferred initial test
for assessing vitamin D status. Compared to 25(OH)
D, 1,25(OH)2 D circulates in the human body at a
very low concentration, making its serum levels
challenging to assess. 1,25 (OH) 2D is a steroid
like hormone. In target cells, such as classic steroid
hormones, it binds to a specific cytoplasmic vitamin
D receptor (VDR); the vitamin D bound to VDR
then translocates to the nucleus, where its effects
are initiated at a transcriptional level. The main
established actions of 1,25(OH)2 D collectively
increase calcium in the body and modulate the
skeleton. It increases the intestinal absorption of
30

calcium and phosphate, decreases renal excretion of
calcium and phosphate, suppresses PTH production,
and regulates osteoblast function and bone resorption.
Clinical utility of1, 25 (OH) 2D Testing
Measuring serum levels of 1,25(OH)2 D should be
considered upon suspicion of deficiency or excess of
1,25(OH)2 D (Table 1).
It is a preferred test for individuals with
hypercalcemia or renal failure in addition to 25(OH)
D testing. In patients with hypercalcemia, both
25(OH) D and 1, 25(OH)2D levels are done to rule
out vitamin D intoxication with disorders that can
increase 1,25(OH)2 D synthesis, such as lymphoma,
sarcoidosis, and other granulomatous diseases.
It may also be used as a second-order test in the
assessment of vitamin D status, especially in
patients with renal disease and in investigation
of vitamin D deficiency when suspecting vitamin
D-dependent rickets due to hereditary deficiency
of renal 1-alpha hydroxylase or end-organ
resistance to 1,25 (OH)2D.
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1,25(OH)2 D may be helpful in diagnosing parathyroid
function disorders.Ahigh serum level of 1,25(OH)2 D, for
example, may suggest of primary hyperparathyroidism,
whereas a normal or low serum level is more likely
found in secondary hyperparathyroidism.
Serial 1,25(OH)2 D levels can be used in monitoring
the efficacy of treatment in patients receiving

1,25(OH)2 D supplementation.
NOTE:
The Section of Chemical Pathology, Department of
Pathology and Laboratory Medicine has initiated the
testing of 1,25 (OH)2D. The reference interval of1,25
(OH)2D used in our laboratory is 19.9-79.3 pg/mL.

Table 1: Conditions causing high or low 1, 25-Dihydroxyvitamin D Levels
Increased 1,25-Dihydroxyvitamin D Levels

Decreased 1, 25-Dihydroxyvitamin D Levels
Chronic kidney disease

Lymphoproliferative disorders

Tumor-induced osteomalacia,

Sarcoidosis,

Use of HIV protease inhibitors

Tuberculosis

Severe 25OHD deficiency

Inflammatory bowel disease

Vitamin D–dependent rickets type 1 (inactivating mutation in the
1-hydroxylase gene)

Hereditary vitamin D-resistant rickets (mutations of vitamin D
receptor coding genes)

Autosomal-dominant hypophosphatemic rickets (mutation of the
gene coding for FGF-23, which prevents its breakdown)

Primary hyperparathyroidism

X-linked hypophosphatemic rickets (mutations that elevate levels
of FGF-23)
Hypoparathyroidism

Answer to LABRAD Quiz
1.1:

Hypoparathyroidism is the most common
cause of hypocalcemia, which is causing
symptoms in this patient. Her presentation
soon after birth suggests presence of
congenital hypoparathyroidism.

1.2:

Serum magnesium levels: Magnesium is
required for optimal activity of parathyroid
gland. Levels are usually low in
hypoparathyroidism.

1.3:

The goal of treatment is to normalise the
levels of calcium, magnesium and
phosphorus. A treatment regimen typically
includes replacing calcium by giving
oral calcium carbonate or gluconate along
with 1 alpha vitamin D.

2.1:

Symptoms of bone pain and weakness
can mean that patient have a coexistent

vitamin D deficiency along with senile
osteoporosis. For many people, the symptoms
are subtle. Yet even without bone symptoms,
inadequate vitamin D levels can pose other
health risks
2.2:

Biochemical tests to measure calcium,
phosphorus, magnesium, vitamin D and
parathyroid hormone and bone turnover
markers can be performed. Depending
upon the symptomatology, tests to screen for
secondary osteoporosis can also be considered.

2.3:

Bone tumor markers (BTM) are helpful
in monitoring bisphosphonate therapy.
Early changes in BTM measure the clinical
efficacy of an anti-resorptive treatment
and to reinforce patient compliance. At
AKUH Clinical Laboratory, N-telopeptide of
Type I collagen is performed.
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Role of Clinical and Radiological Correlation
in Orthopaedic Pathology
Dr Nasir Ud Din
Histopathology

Clinical and radiological information required
for the pathological diagnosis of bone tumours.
Histopathological assessment of a bone tumour needs
to take into account the clinical background and
features of the lesion, its radiological appearances
and the results of relevant laboratory investigations.
Diagnostic evaluation and treatment should optimally
be carried out at a centre which specialises in the
diagnosis and treatment of bone tumours.

of infection need to be distinguished from those
associated with the growth of a bone tumour, such
as Ewing sarcoma. Information regarding a preexisting skeletal condition should be provided,
including developmental conditions where there
are multiple skeletal lesions (e.g fibrous dysplasia,
osteochondromatosis). It is also important to receive
information on any relevant extraskeletal disease (e.g
history of carcinoma) elsewhere in the body.
The results of laboratory investigations which
Relevant clinical information should be provided on the
may help in evaluating a bone lesion should be
pathology request form and its content should be
communicated to the reporting pathologist. Details
recorded in the final pathology report. The age of the
of the white blood cell count and erythrocyte
patient is crucial for bone tumour diagnosis as a number
sedimentation rate should be noted if there is
of bone tumours, both benign and malignant, tend to
a possibility that the lesion is a bone infection,
develop most commonly within a given age range (Table 1).
eosinophilic granuloma, leukaemia or other
haematological malignancy. Ewing sarcoma and
Table 1: Peak Age Predilection of Bone Tumors
‘toxic’ osteoclasts may present with clinical and
laboratory features
Age (years)
Benign
Malignant
that resemble
Less than 20 Nonossifying fibroma, simple bone
Ewing Sarcoma, osteosarcoma
osteomyelitis.
cyst,aneurysmal bone cyst, chondroblastoma,
(conventional, periosteal, telangiectatic),
If myeloma is
Langerhans cell histiocytosis, osteoblastoma,
Leukemia,neuroblastoma,
suspected, protein
osteoid osteoma, osteofibrous dysplasia,
electrophoresis for
chondromyxoid fibroma, fibrous dysplasia,
the identification
enchonroma
20-40
Enchondroma, giant cell tumor, osteoblastoma, Osteosarcoma (parosteal), adamantinoma of monoclonal
immunoglobulin
osteoid osteoma, chondromyxoid fibroma,
components in the
fibrous dysplasia
serum or urine should
More than 40 Fibrous dysplasia, Paget disease
Metastatic disease (most common),
Chondrosarcoma,myeloma, Non-hodgkin be undertaken.
Laboratory tests
lymphoma, Osteosarcoma (secondary)
reflecting bone
Some tumours and tumour-like lesions have a
turnover, such as the serum calcium, phosphate
predilection to arise in certain bones,e.g simple bone
and alkaline phosphatase should also be known,
cyst occurs most often in the proximal humerus of
particularly if there is a need to exclude a metabolic
a child or adolescent (Table 2). Most bone tumours
cause for the development of a bone tumour, such
present with bone pain and swelling. Bone pain
as a “brown tumour” of hyperparathyroidism or
is dull, aching and characteristically worse at
Paget’s disease. The alkaline phosphatase may also
night characteristically seen in osteoid osteoma.
be elevated in osteosarcoma, ‘blastic’ metastases,
Rapid growth is characteristic of some malignant
fracture, polyostotic fibrous dysplasia and other
tumours but is also seen in some benign tumours
conditions. The acid phosphatase may be elevated in
and tumour-like lesions, such as aneurysmal bone
prostate carcinoma.
cyst, eosinophilic granuloma and osteomyelitis.
A history of trauma may be notable in cases
Radiological information is essential for bone
where a post-traumatic lesion (eg haematoma) is
tumour diagnosis and it is strongly recommended
a possible diagnosis. Local and systemic signs
that, wherever possible, the pathologist should
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within cartilage tumour or ossification within a
bone-forming tumour).
Location
Benign
Malignant
The interface between the
Chondroblastoma, Giant cell
Epiphyseal
Clear cell chondrosarcoma (very rare
lesion and surrounding
tumor,Intraosseous ganglion/
tumor)
bone, particularly
geode(associated with arthritis)
whether the lesion is
Metaphyseal
well or poorly defined,
should be noted as this
Medullary
Conventional
Simple bone cyst,Aneurysmal bone cyst,
may favour a particular
Enchondroma, Fibrous dysplasia,Osteomy osteosarcoma,chondrosarcoma,
benign or malignant
elitis,Localized Langerhans cell histiocy- metastasis, myeloma, lymphoma,
tosis, chondromyxoid fibroma
diagnosis. A sclerotic
rim is commonly present
Cortical
Metastasis (especially lung)
Fibrous cortical defect, osteoid osteoma
around slow growing
Juxtacortical Juxtacortical chondroma
Periosteal osteosarcoma, parosteal osteolesions and usually points
sarcoma, juxtacortical chondrosarcoma
to a benign diagnosis.
Diaphysis
A non-sclerotic margin
Medullary
is usually found around
Fibrous dysplasia, Localized Langerhans Ewing sarcoma, lymphoma, myeloma,
Metastatic disease
cell histiocytosis
a more rapidly growing
bone lesion; malignant
Cortical
Adamantinoma, Metastasis
Osteofibrous dysplasia
(especially lung)
lesions are commonly
poorly defined and have a
personally view the radiological images of a bone
broad zone of transition.
tumour before issuing a diagnostic report. Where this
is not possible, it should be recorded in the pathology
The pattern of bone destruction should be identified
report.
as it indicates the rate of growth of a bone lesion.
A geographic pattern of bone destruction is
The precise anatomical location of a lesion in bone
characterized by the presence of well-circumscribed
is important because tumours have a tendency not
lytic areas (maximum dimension more than 1
only to develop more commonly in certain bones
cm) with a well-defined margin; this reflects
but also more frequently to involve the particular
the slow growth rate of these lesions, which
anatomical region of an affected bone (Table 3). It
are usually benign tumours (e.g non-ossifying
should also be evident from the radiology whether a
fibroma) or locally aggressive/low-grade malignant
lesion has originated in bone or extended into it from
tumours (e.g giant cell tumour of bone, low-grade
surrounding soft tissues.
chondrosarcoma). A rim of sclerosis between normal
host bone and the lytic area may or may not be
Table 3: Specific Sites of Selected Tumours
present. A moth-eaten pattern of bone destruction
is characterized by the presence of multiple
Tumor
Location
small lytic areas (usually 2-5 mm) separated by
Adamantinoma
Anterior cortex of tibia
identifiable bone; this indicates an aggressive pattern
of growth and is most often seen in malignant
Osteofibrous dysplasia
Anterior cortex of tibia
neoplasms, although it can be seen in some forms
Parosteal osteosarcoma
Posterior cortex of distal femur
of osteomyelitis and langerhans cell histiocytosis.
Periosteal desmoid
Posterior cortex of distal femur
A permeative pattern of bone destruction is
characterized by diffuse marrow involvement in
Osteoblastoma
Posterior elements of spine
which there are multiple tiny lytic areas (< 1 mm
Aneursmal bone cyst
Posterior elements of spine
maximum dimension). This is usually accompanied
Haemangioma
Vertebral bodies
by a broad zone of transition and reflects rapid
growth of a bone lesion. A permeative pattern occurs
Chordoma
Clivus, vertebral bodies, sacrum
in malignant tumours such as Ewing sarcoma and
Epidermal inclusion cyst Terminal tuft of phalanx
osteosarcoma, but can also be seen in some benign
Glomus tumour
Terminal tuft of phalanx
entities such as osteomyelitis and langerhans cell
histiocytosis.
Simple bone cyst
Calcaneous
Table 2. Typical Locations of Bone Lesions

The matrix composition of the lesion may point to
specific diagnostic possibilities (e.g calcification

Radiological evidence of extension of the tumour
through the bone cortex and involvement of
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surrounding soft tissue should be noted as this
provides evidence of a locally aggressive or
malignant tumour. The nature of the periosteal
reaction associated with a bone lesion oftens reflects
the growth rate of the tumour. When the tumour
grows slowly, the periosteum forms a thick layer
of bone. Multiple layers of periosteal new bone are
formed when there is a succession of fast and slow
growth phases associated with the enlargement of the
underlying lesion. The presence of tumour on both
sides of the cortex (which is not yet destroyed) often
indicates a very aggressive lesion.

The presence of multiple lesions within bone
should be determined as this may suggest
particular conditions such as multiple cartilage
tumours (e.g enchondromatosis, multiple
osteochondromas) or langerhans cell histocytosis,
brown tumor, fibrous dysplasia, multiple
myeloma. This feature is also useful in assessing
whether a malignant tumour is more likely to be
primary or secondary. With regard to primary
malignant bone tumours, it may also point to a
diagnosis of multifocal osteosarcoma or metastatic
Ewing sarcoma.

Stop at One. Make your first break your last!

CME Seminar on ‘World Osteoporosis Day’
Dr Lena Jafri

Chemical Pathology

The Metabolic Bone Disease Forum of AKU and the
Department of Pathology & Laboratory Medicine,
Aga Khan University in collaboration with Pakistan
Society of Chemical Pathology, Pakistan Orthopedics
Association and Pakistan Society of Rheumatology,
organized a CME Seminar on ‘World Osteoporosis
Day’ on Tuesday, October 20, 2015, at the Medical
College, Aga Khan University, Karachi Pakistan.
Renowned experts from Aga Khan University
delivered talks and complicated cases related to
osteoporosis were discussed by invited experts. Dr
Imran Siddiqui, Associate Professor and Interim
Chair, Department of Pathology & Laboratory
Medicine who welcomed the participants and
discussed the importance of such academic activities.
He appreciated the efforts of Metabolic Bone Disease
Forum in creating awareness of bone health on
‘World Osteoporosis Day’.
The links between vitamin D and osteoporosis were
highlighted by Dr Aysha Habib Khan, Associate
Professor and Section Head of Chemical Pathology,
Department of Pathology & Laboratory Medicine.
She described the work of Metabolic Bone Research
Group and Metabolic Bone Disease Forum which
have a strong record of activity over the past years.
She gave an overview of the burden of osteoporosis
in Pakistan and shared findings of various studies
from Aga Khan University Hospital. She shared
the reality that most hospitals and clinics fail to
capture the first fracture – leaving patients open
34

Dr Aysha Habib Khan delivering a talk on Burden of Osteoporosis in Pakistan

to a future of suffering and debility. Over 80% of
fracture patients are never offered screening and/or
treatment for osteoporosis, despite the fact that there
are effective medications that can reduce fracture risk
by as much as 30–70 %. She also emphasized on the
importance of screening with appropriate laboratory
investigation in the assessment of metabolic bone
diseases.
Dr Maseeh uz Zaman, Associate Professor and
Section Head Nuclear Medicine, Department
of Radiology gave a comprehensive talk on
interpretation and limitations of Dual Energy X-ray
Absorptiometry (DXA) Scan. He discussed the
sensitivity of DXA reporting with real life cases. He
further explained how DXA findings can assist in
managing osteoporosis. Additionally he talked about
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FRAX, the fracture risk assessment tool a free webbased clinical scale assessing the 10-year fracture
risk and need for lifestyle advice, DXA scanning or
preventive treatment.
Ms. Muzamila Mughal, a Nutritional Expert, who
highlighted the importance of diet, exercise and
lifestyle for good musculoskeletal health, including
its role in maintaining future mobility and quality
of life. In line with World Osteoporosis theme 2015
‘Serve up bone strength throughout life’, she stressed
that adequate dietary intake of calcium and vitamin
D is essential for good bone health.
Management of primary osteoporosis was discussed
by Dr. Masood Umar, Associate Professor and
Orthopedic Surgeon. The key aspect of his discussion
was a comprehensive treatment strategy for patients
with osteoporosis. He identified the pros and cons
of various pharmacological therapies available for
osteoporosis.

One of the presenters with the Dean Medical College, Dr Farhat Abbas
and Acting Chair Dept. of Pathology and Laboratory Medicine,
Dr Imran Siddiqui

undertreated in an estimated one million patients
who receive glucocorticoid therapy for a wide
variety of medical disorders, emphasizing that
glucocorticoids are the most common cause
of secondary osteoporosis and non-traumatic
osteonecrosis.

Dr Lena Jafri Assistant Professor and Member
Executive Council Pakistan Society of Chemical
Pathology emphasized on the need to identify
secondary osteoporosis in clinical set-up. She
presented an outline of the approach to secondary
osteoporosis. She gave an insightful talk on clinical
utility of available biochemical and radiological
investigations for identifying secondary osteoporosis
and provided the audience with a diagnostic
approach. Additionally she emphasized the
importance of the need for a Pakistani fracture risk
assessment tool and discussed the impediments
in creating one, like lack of fracture registries and
paucity of data on post- fracture mortality rates.
Dr Mehmood Riaz, Assistant Professor, Department
of Medicine, gave an enlightening talk on steroid
induced osteoporosis. He stated that glucocorticoidinduced osteoporosis is under recognized and

Real life challenging cases of osteoporosis were
presented by Dr Hafsa Majid, Resident Chemical
Pathology and panel of experts pitched in with their
expertise on diagnosis and management. Panel of
experts comprised of renowned endocrinologist.
Saeed Maher, rheumatologist Dr. Saleha Ishaq,
orthopaedic surgeon Dr. Amin Chinoy and Director
Kiran Hospital Dr. Akhter. Many questions were
elicited which made for great discussion among all.
The closing remarks were delivered by Dean
Medical College, Dr Farhat Abbas who appreciated
the role of faculty in holding a seminar on World
Osteoporosis Day and in creating awareness of
an ignored disease affecting a large part of our
population. The CME seminar was successful
in bringing together delegates from the different
disciplines. The osteoporosis seminar exposed
the risk factors, highlighted the preventive tools,
diagnostic caveats
and management
strategies of
osteoporosis. The
attendees were
remarkably diverse
and showed high level
of enthusiasm. The
goal of providing a
forum of information
exchange among all
the professionals was
successfully
Group picture of presenters and members of Pakistan Society of Chemical Pathology at the CME Seminar on World
achieved.
Osteoporosis Day at AKUH, Karachi Pakistan
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